2008-SCI-IF

合集下载

FOOD-SCI影响因子(汇总)

0.8 0.765 0.714 0.702 0.697 0.662 0.656 0.612 0.562 0.56 0.558 0.511 0.482 0.472 0.471 0.471 0.462 0.41 0.365 0.35 0.313 0.311 0.282 0.258 0.233 0.221 0.189 0.136
3.458
2.619 2.168 2.416
2.292
1.733
1.360
0.593 1.223 0.947
0.2 0.774 1.024 0.404
J FOOD BIOCHEM FOOD DRUG LAW J J FOOD NUTR RES FOOD SCI TECHNOL INT AGR FOOD SCI J FOOD LIPIDS J FOOD PROCESS ENG J MUSCLE FOODS J FOOD SAFETY BRIT FOOD J FOOD BIOTECHNOL FOOD BIOPROD PROCESS J APPL BOT FOOD QUAL CZECH J FOOD SCI J FOOD QUALITY J FOOD DRUG ANAL ITAL J FOOD SCI FOOD AUST FOOD SCI TECHNOL RES FOOD AGR IMMUNOL J FOOD PROCESS PRES ECOL FOOD NUTR J FOOD AGRIC ENVIRON J FOOD HYG SOC JPN IRISH J AGR FOOD RES J FOOD SCI TECH MYS AGRO FOOD IND HI TEC J JPN SOC FOOD SCI FOOD BIOPROCESS TECH FOOD ANAL METHOD FOOD ADDIT CONTAM B INT DAIRY J J DAIRY RES J DAIRY SCI INT J DAIRY TECHNOL FLEISCHWIRTSCHAFT INT J FOOD ENG VET CLIN N AM-FOOD A DAIRY SCI TECHNOL AUST J DAIRY TECHNOL J AQUAT FOOD PROD T KOREAN J FOOD SCI AN

40种肿瘤类SCI杂志_影响因子IF小于5_特点

美国国立癌症研究所（NCI）、疾病控制与预防中心（CDC）、美国癌症学会（ACS）、北美肿瘤登记中心联合会（NAACCR）四大权威机构联合发布的这项报告指出由中国抗癌协会主办、目前在肿瘤学院的英文杂志《Chinese Journal of Cancer Research》（中国癌症研究）被SCI和JCR正式收录。

英文杂志《Chinese Journal of Cancer Research》已于2013年1月被PubMed正式收录，该杂志于2008年已被SCI（科学引文索引）收录。

这是国内唯一一家肿瘤学英文杂志(《Chinese Journal of Cancer Research》)同时被PubMed和SCI收录4-5分多的International journal of cancer, or European journal of cancer,or Cancer.IF=7-8的肿瘤类期刊，只有Oncogene 和Cancer Research，而Cancer Research在字数和图表数以及Western结果等方面有相当近乎苛刻的要求。

杂志名称：Journal of cancer research and clinical oncology专业领域：肿瘤学杂志国家：德国影响因子：2010 ；2009 ；2008 看来影响因子在涨但涨幅不大投稿日期：2011-6-8?投稿方式：在线投稿?修改方式：minor revision 2011-7-13接受日期：2011-7-13?在线出版：2011-7-26印刷出版：2011-8是否收版面费：无版面费包括彩图个人评价：1.效率高，如果据稿1周之内编辑不送外审直接给答复不耽误改投它刊；如果接受会转交Springer 从校稿到在线出版再到印刷出版时间不会太长；所以如果毕业或晋升急用，比较适合不耽误工夫2.比较友好：浏览了该杂志的文章好多都是中国人发表的所以不会对中国有歧视3. 比较好中，主要偏临床或临床与基础结合的文章如临床病例分析临床病理组织学研究等；关键是创新性要有这一点是关键。

重庆医科大学(教学研究)系列教授专业技术职务任职资格

重庆医科大学(教学/研究)系列教授专业技术职务任职资格评审综合情况(公示)表填报单位: 基础医学院学科: 生物化学与分子生物学填表时间：2013年7月15日
注：1、此表由申报人填写，使用A3纸打印；
2、自然科学研究论文必须是论著或有中(英)文摘要、研究方法、数据分析、结果、讨论、参考文献等完整格式的论文且字数在2000字以上。

文科研究论文字数必须在3000字以上。

3、其他文章请注明题目名称、杂志名称、年卷期页、类别，著作及教材请注明参编或主编章节、字数、出版社名称、时间。

参考文献目录

参考文献目录第一章疾病概论[1]肖献忠. 病理生理学[M]. 2版. 北京：高等教育出版社，2008.[2]金惠铭，王建枝. 病理生理学[M]. 7版. 北京：人民卫生出版社，2008[3]Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell [M], 5th ed, New Y ork,Garland Science, 2008.[4]Huether SE, McCance KL. Understanding Pathophysiology [M], 4th ed, St. Louis, MO,Mosby Elsevier, 2008.[5]Copstead LC, Banasik JL. Pathophysiology [M], 4th ed, St. Louis, Missouri, Saunders Elsevier,2010[6]Gerber A, Hentzelt F, Lauterbach KW. Can evidence-based medicine implicitly rely oncurrent concepts of disease or does it have to develop its own definition [J]? J Med Ethics 2007; 33(7): 394-9.[7]Ideker T, Sharan R. Protein networks in disease [J]. Genome Res 2008; 18(4): 644-52.[8]Holtz TH, Holmes SM, Stonington S, et al. Health is still social: contemporary examples inthe age of the genome [J]. PLoS Med 2006; 3(10): e419.[9]Baudot A, Gómez-López G, V alencia A. Translational disease interpretation with molecularnetworks [J]. Genome Biol 2009; 10(6): 221.[10]C rews D, McLachlan JA. Epigenetics, evolution, endocrine disruption, health, and disease [J].Endocrinology. 2006; 147(6 Suppl): S4-10.第二章疾病的系统生物学[1]Kitano H. Systems biology. Science 2002; 295(5560): 1662-1664.[2]Hood L, Rowen L, Galas DJ, Aitchison JD. Systems biology at the Institute for SystemsBiology. Brief Funct Genomic Proteomic 2008; 7(4): 239-248.[3]Hood L. Systems biology: integrating technology, biology, and computation. Mech AgeingDev 2003; 124(1): 9-16.[4]Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu RevGenomics Hum Genet 2001; 2: 343-372.[5]蒋太交，薛艳红，徐涛. 系统生物学—生命科学的新领域. 生物化学与生物物理进展2004; 31(11): 957-964.[6]Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functionalvalidation and mechanisms. Hum Mol Genet 2008; 17(R2): R174-179.[7]Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring.Proc Natl Acad Sci USA 2009; 106(34): 14187-14188.[8]CB Clish, E Davidov, M Oresic, et al.Integrative biological analysis of the APOE*3-leidentransgenic mouse[J].OMICS,2004,8(1):3-13.[9]Miehailova A, MeCulloch A.Model study of A TP and ADP buffering, transport of Ca2+ andMg2+, and regulation of ion pumps in ventricular myocyte. Biophys J 2001;81:614-629．[10]W ee KB, Aguda BD. Akt versus P53 in a network of oncogenes and tumor suppressor genesregulating cell survival and death．Biophys J, 2006, 91(3): 857-865.第三章细胞信号转导与疾病[1]卢建, 余应年, 徐仁宝主编. 受体信号转导系统与疾病[M]. 济南: 山东科技出版社.1999,1~18, 164~189, 558~596, 624~641.[2]卢建. 细胞信号转导异常与疾病[M]. 见金惠铭, 王建枝主编．病理生理学. 北京: 人民卫生出版社. 2007.[3]Toren Finkel and J. Silvio Gutkind (Editors-in-Chief): Signal transduction and humandisease [M]. John Wiley & Sons. Inc, 2003.[4]Friedrich Marks, Ursula Klingmüller, and Karin Müller-Decker (Editors-in-Chief):Cellular Signal Processing: An Introduction to the Molecular Mechanisms of Signal Transduction [M]. Garland Science, 2008.[5]McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK andPI3K/PTEN/AKT pathways in malignant transformation and drug resistance [J]. Adv Enzyme Regul. 2006; 46:249-79.[6]Gutkind JS. Regulation of mitogen-activated protein kinase signaling networks by Gprotein-coupled receptors. Sci STKE. 2000 Jul 11; 2000(40):RE1.[7]Ludwig MG,V anek M,Guerini D,Gasser JA,Jones CE,Junker U,Hofstetter H,WolfRM,Seuwen K. Proton-sensing G-protein-coupled receptors. Nature. 2003 Sep 4;425(6953):93-8.第四章细胞死亡[1]Kroemer G, Galluzzi L, V andenabeele P, et al. Classification of cell death: recommendationsof the Nomenclature Committee on Cell Death 2009 [J]. Cell Death Differ. 2009; 16(1): 3-11.[2]Sperandio S, Poksay K, de BI et al. Paraptosis: mediation by MAP kinases and inhibition byAIP-1/Alix [J]. Cell Death Differ; 2004;11(10):1066-1075.[3]Le Bot N. Entosis: cell death by invasion [J]. Nat Cell Bio. 2007; 9:1346.[4]杨惠玲, 潘景轩, 吴伟康. 高级生理病理学[M].北京：科学出版社, 2006[5]Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochromec-dependent caspase activation by eliminating IAP inhibition [J]. Cell.2000; 102(1):33-42. [6]Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released frommitochondria [J]. Nature. 2001; 412:95-99[7]Savill J, Fadok V. Corpse clearance defines the meaning of cell death [J]. Nature. 2000;407(6805):784-788.[8]Kroemer G, Levine B. Autophagic cell death: the story of a misnomer [J]. Nat Rev Mol CellBiol. 2008; 9(12):1004-1010[9]He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy [J]. AnnuRev Genet. 2009; 43: 67–93.[10]Liu Y, Schiff1 M, Czymmek K, et al. Autophagy genes are essential for limiting the spread ofprogrammed cell death associated with plant innate immunity [J]. Cell. 2005; 121:567-577.[11]Y u L, Alva A, Su H, et al. Regulation of an A TG7-beclin 1 program of autophagic cell deathby caspase 8 [J]. Science. 2004; 304:1500-1502.第五章水、电解质及酸碱平衡紊乱[1]王树人. 钙磷代谢与钙磷代谢障碍. 见金惠铭主编, 病理生理学,第五版,北京: 人民卫生出版社,2000,45-55[2]M.B. Cannell and C. Soeller. Mechanisms Underlying Calcium Sparks in Cardiac Muscle. J.Gen. Physiol. Volume 113 March 1999 373–376[3]Mitchell L. Halperin, Mare B. Goldstein. Fluid, Electrolyte, and Acid-Base Physiology.(3rdEdition). Bijing: Science press, Harcourt Asia,2001, 227-484.[4]Gillian Edwards, Arthur H. Weston. Potassium and potassium clouds inendothelium-dependent hyperpolarizations. Pharmacol Res. 2004,49(4?),535~541.[5]刘长金. 尿的生成与排出. 见姚泰主编. 生理学.第6版.北京: 人民卫生出版社,2003.215~242.第六章缺氧[1]肖献忠. 病理生理学[M]. 北京：高等教育出版社.2008. 63-73[2]李桂源. 病理生理学[M]. 北京：人民卫生出版社. 2010. 220-235[3]高钰琪. 高原病理生理学[M]. 北京：人民卫生出版社.2005. 32-55[4]Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling:cellular and molecular mechanisms [J]. Circ Res. 2006; 99(7): 675-691.[5]Ward JP, McMurtry IF. Mechanisms of hypoxic pulmonary vasoconstriction and their rolesin pulmonary hypertension: new findings for an old problem [J]. Curr Opin Pharmacol. 2009;9(3): 287-296.[6]Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases [J]. Nat Rev Mol Cell Biol.2004; 5(5): 343-354.[7]Adams JM, Difazio LT, Rolandelli RH, et al. HIF-1: a key mediator in hypoxia[ J]. ActaPhysiol Hung. 2009; 96(1): 19-28第七章应激反应与疾病[1]金惠铭,王建枝. 病理生理学[M]. 第7版. 北京：人民卫生出版社,2008[2]张海鹏, 吴立玲. 病理生理学[M]. 第1版. 北京：高等教育出版社,2009[3]McCance KL, Huether SE, Brashers VL, et al. Pathophysiology: The biologic basis fordisease in adults and children [M], 6th ed, Philadelphia, PA, USA, Mosby Elsevier, 2010[4]Copstead LC, Banasik JL. Pathophysiology [M], 4th ed, St. Louis, Missouri, Saunders Elsevier,2010[5]McEwen BS, Wingfield JC. What is in a name? Integrating homeostasis, allostasis and stress[J]. Horm Behav. 2010; 57(2): 105-111[6]Pruett SB. Stress and the immune system [J]. Pathophysiology 2003;9(3):133-153[7]Steptoe A. Handbook of Behavioral Medicine: Methods and Applications[M]. New Y ork,Springer Science+Business Media, 2010[8]Tausk F, Elenkov I, Moynihan J. Psychoneuroimmunology [J]. Dermatol Ther2008;21(1):22-31.[9]McEwen BS, Seeman T. Protective and damaging effects of mediators of stress. Elaboratingand testing the concepts of allostasis and allostatic load [J]. Ann N Y Acad Sci 1999;896:30-47.[10]M iksa M, Das P, Zhou M, et al. Pivotal role of the alpha(2A)-adrenoceptor in producinginflammation and organ injury in a rat model of sepsis [J]. PLoS One 2009; 4(5):e5504.第八章炎症[1]肖献忠. 病理生理学[M]. 2版. 北京：高等教育出版社，2008.[2]李桂源. 病理生理学[M]. 2版. 北京：人民卫生出版社，2010.[3]Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyteadhesion cascade updated [J]. Nat Rev Immunol, 2007; 7(9): 678-689.[4]Dalal S, Zhukovsky DS. Pathophysiology and management of fever [J]. J SupportiveOncology, 2006; 4(1): 9-16.[5]Barie PS, Hydo LJ, Pieracci FM,et al. Multiple organ dysfunction syndrome in criticalsurgical illness [J]. Surgical Infections, 2009; 10(5): 369-377.[6]Castellheim A, Brekke OL, Espevik T, et al. Innate immune responses to danger signals insystemic inflammatory response syndrome and sepsis [J]. Scand J Immunol, 2009; 69: 479-491.[7]Simkova V, Baumgart K, Radermacher P, et al. Y ear in review 2006: Critical care-multipleorgan failure, sepsis, and shock [J]. Crit Care, 2007; 11(4):221-227.[8]Matsuda N, Hattori Y. Systemic inflammatory response syndrome (SIRS): molecularpathophysiology and gene therapy [J]. J Pharmacol Sci, 2006; 101(3):189-198.第九章休克[1]赵克森，金丽娟. 休克的细胞和分子基础[M]. 北京：科学出版社，2002：55-57.[2]赵克森. 重症难治性休克发生机制的若干进展[J]. 解放军医学杂志，2005，30 (7)：552-554.[3]刘良明. 战伤休克的液体复苏进展[J]. 解放军医学杂志，2005，30 (7)：561-565.[4]Goldman L, Ausiello D. Cecil Textbook of Medicine, 22nd edition Single V olume [M].U.S.A: W.B. Saunders Company, 2003, 609-622.[5]Fall PJ, Szerlip HM. Lactic acidosis: from sour milk to septic shock [J]. J Intensive Care Med.2005, 20(5): 255-271.[6]Zhao KS. Hemorheologic events in severe shock [J]. Biorheology 2005, 42: 463-477.[7]Cuzzocrea S, Wang ZQ. Role of poly(ADP-ribose) glycohydrolase (PARG) in shock,ischemia and reperfusion [J]. Pharmacol Res. 2005, 52(1):100-108.[8]Rice TW, Bernard GR. Drotrecogin alfa (activated) for the treatment of severe sepsis andseptic shock [J]. Am J Med Sci., 2004, 328(4):205-214.[9]Dellinger RP, Carlet JM, Masur H, et al.Surviving Sepsis Campaign guidelines formanagement of severe sepsis and septic shock. Crit Care Med [J]. 2004; 32:858 –873. [10]Cohen J. Recent developments in the identification of novel therapeutic targets for thetreatment of patients with sepsis and septic shock [J]. Scand J Infect Dis. 2003, 35(9):690-696.[11]Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock[J]. Curr Opin Crit Care. 2009 Oct;15(5):392-7.[12]Flynn A, Chokkalingam Mani B, Mather PJ. Sepsis-induced cardiomyopathy: a review ofpathophysiologic mechanisms [J]. Heart Fail Rev. 2010 Nov;15(6):605-11.第十章缺血-再灌注损伤[1]金惠铭，王建枝. 病理生理学[M]. 第六版. 北京：人民卫生出版社，2003.[2]欧阳静萍，卢彦珍. 缺血再灌注损伤. 见肖献忠，主编. 病理生理学[M]. 第二版. 北京：高等教育出版社，2008.[3]王万铁. 缺血-再灌注损伤. 见金惠铭，王建枝，主编.病理生理学[M]. 第七版. 北京: 人民卫生出版社，2008.[4]Cameron D, Nicolaas R, Sruti S M, et al. Role of the anion nitrite in ischemia-reperfusioncutoprotection and therapeutics [J]. Cardiovasc Res, 2007, 75(2): 327-338.[5]Charles D, Collard MD, Simon G,et al.Pathophysiology, Clinical Manifestations, andPrevention of Ischemia–Reperfusion Injury [J]. Anesthesiology, 2001, 94(6): 1133-1138. [6]de Groot H, Rauen U. Ischemia-reperfusion injury: processes in pathogenetic networks: areview [J]. Transplant Proc, 2007, 39(2): 481-484.[7]Gross GJ, Auchampach JA. Reperfusion injury: Does it exist ? [J]. J Mol Cell Cardiol, 2007,294: 632-641.[8]Joshua M. Thurman. Triggers of inflammation after renal ischemia/reperfusion [J]. ClinImmunol, 2007, 123(1): 7-13.[9]Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement areimportant mediators of tissue damage in acute myocardial infarction [J]. J Exp Med, 1999, 190(12): 1733-1740.[10]Tapati C, Amritlal M, Malay M, et al. Complement activation in heart diseases: Role ofoxidants [J]. Cell Signal, 2000, 12: 607–617.第十一章肿瘤的病理生理学[1]王迪洵，金惠铭. 人体病理生理学[M]. 3版. 北京：人民卫生出版社，2008: 445-536.[2]李桂源，吴伟康，欧阳静萍. 病理生理学[M]. 2版. 北京：人民卫生出版社，2010: 303-326.[3]Hannon R A, Pooler C, Porth C M, et al. Porth Pathophysiology: Concepts of Altered HealthStates [M]. 1st ed. Canada: Wolters Kluwer /Lippincott Williams & Wilkins, 2010: 150-188.[4]Thiery J P, Acloque H, Huang R Y, et al. Epithelial-mesenchymal transitions in developmentand disease [J]. Cell, 2009, 139:871-890.[5]Bernstein BE, Stamatoyannopoulos JA, Costello JF, et al. The NIH Roadmap EpigenomicsMapping Consortium [J]. Nat Biotechnol, 2010, 28:1045-1048.[6]Jones PA, Baylin SB. The epigenomics of cancer [J]. Cell, 2007, 128: 683–692.[7]Bomken S, Fiser K, Heidenreich O, et al. Understanding the cancer stem cell [J]. Br J Cancer,2010, 103: 439-445.第十二章循环系统的病理生理学[1]杨永宗. 动脉粥样硬化性心血管病基础与临床[M]. 2版. 北京：科学出版社，2009.[2]王迪浔，金惠铭.人体病理生理学[M] . 3版. 北京：人民卫生出版社，2008[3]陆再英，钟南山. 内科学[M]. 7版. 北京：人民卫生出版社，2008[4]Copstead LC, Banasik JL. Pathophysiology [M], 4th ed, St. Louis, Missouri, SaundersElsevier, 2010[5]Rossier BC, Schild L.Epithelial sodium channel: mendelian versus essential hypertension [J].Hypertension.2008; 52: 595 - 600[6]Zernecke A, Weber C.Chemokines in the vascular inflammatory response of atherosclerosis[J]. Cardiovasc Res . 2010; 86: 192 - 201.[7]Dickstein K, Cohen-Solal A, Filippatos G, et al.ESC guidelines for the diagnosis andtreatment of acute and chronic heart failure 2008 [J]. Eur J Heart Fail. 2008; 10(10): 933-989.[8]Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010comprehensive heart failure practice guideline [J]. J Card Fail. 2010; 16(6): e1-194.[9]Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACCF/AHA guidelines forthe diagnosis and management of heart failure in adults [J]. J. Am. Coll. Cardiol.2009;53;1343-1382[10]Weisfeldt ML, Zieman SJ. Advances in the prevention and treatment of cardiovasculardisease [J]. Health Affairs, 2007;26(1): 25-37.第十三章呼吸系统的病理生理学[1]王迪浔，金惠铭. 人体病理生理学[M].第3版.北京：人民卫生出版社，2008.[2]毛宝龄，钱桂生. 呼吸衰竭[M].上海：上海科学技术出版社，2005.[3]朱蕾，刘又宁，钮善福. 临床呼吸生理学[M].第一版. 北京：人民卫生出版社，2008.[4]金惠铭. 病理生理学[M].上海：复旦大学出版社，2005.[5]肖献忠. 病理生理学[M]. 第2版.北京：高等教育出版社，2008.[6]C. Roussos, A. Koutsoukou. Respiratory failure [J]. Eur Respir J. 2003; 22: Suppl. 47, 3s–14s.[7]Mortelliti MP, Manning HL. Acute Respiratory Distress Syndrome [J]. American FamilyPhysician. 2002, 65(9):1823-1830.[8]Udobi KF, Childs ED, Touijer K. Acute Respiratory Distress Syndrome [J]. American FamilyPhysician. 2003, 67(2): 315-322.[9]凌亦凌，黄新莉. 呼吸衰竭发病机制的研究进展[J]. 临床内科杂志. 2004，21（10）：649-652.[10]崔德健. 急性呼吸窘迫综合征发病机制的现代认识[J].感染、炎症、修复.2001，2（3）：125-127.第十四章泌尿系统的病理生理学[1]金惠铭，王建枝. 病理生理学[M]. 7版. 北京：人民卫生出版社，2008[2]肖献忠. 病理生理学[M]. 2版. 北京：高等教育出版社，2008.[3]Hilton R.Acute renal failure. BMJ, 2006.[4]Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidneydysfunction [J]. Curr Opin Nephrol Hypertens. 2009,18(3): 181–188.[5]Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism:epidemiology and mechanisms [J].Curr Opin Pulm Med.2009,15(5): 408–412.[6]Patel TV, Singh AK. Role of vitamin D in chronic kidney disease [J].SeminNephrol.2009,29(2):113–121.[7]Madero M, Sarnak MJ, Wang X, et al. Uric Acid and Long-term Outcomes in CKD [J]. Am JKidney Dis.2009,53(5):796–803.[8]Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronicrenal insufficiency [J]. N Engl J Med.2006,354(2):131-40.[9]Carrero JJ, Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronickidney disease:a hypothesis proposal [J]. Clin J Am Soc Nephrol. 2009,4(11):49-55.[10]Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights fromanimal models [J]. Kidney Int.2005,67(2):404-19.[11]Chevalier RL, Forbes MS.Generation and evolution of atubular glomeruli in the progressionof renal disorders [J]. J Am Soc Nephrol.2008,19(2):197-206.第十五章消化系统的病理生理学[1]王迪浔，金惠铭. 人体病理生理学[M]. 第三版. 北京：人民卫生出版社，2008.[2]金惠铭，王建枝. 病理生理学[M]. 7版. 北京：人民卫生出版社，2008[3]梁扩寰，李绍白. 肝脏病学[M].第二版.人民卫生出版社，2003.[4]Huether SE, McCance KL. Understanding Pathophysiology [M], 4th ed, St.Louis, MO,Mosby Elsevier, 2008.[5]Copstead LC, Banasik JL. Pathophysiology [M], 4th ed, St. Louis, Missouri, SaundersElsevier, 2010.[6]Thomas E. Andreoli. Cecil essentials of medicine [M], 5th ed, Health Science Asia, ElsevierScience, 2001.[7]Bernal W, Auzinger G, Dhawan A, Wendon J, Acute liver failure [J]. Lancet. 2010;376(9736):190-201.[8]Seyan AS, Hughes RD, Shawcross DL, Changing face of hepatic encephalopathy: role ofinflammation and oxidative stress[J]. World J Gastroenterol. 2010; 16(27):3347-57.[9]V enkat D, V enkat KK. Hepatorenal syndrome[J]. South Med J. 2010;103(7):654-61.第十六章神经系统的病理生理学[1]肖海鹏，杨惠玲. 临床病理生理学[M]. 1版. 北京：人民卫生出版社，2009.[2]王万铁. 病理生理学[M]. 1版. 北京：人民卫生出版社，2008.[3]韩济生. 神经科学[M]. 3版. 北京：北京大学医学出版社，2009.[4]Bodhankar SL, V yawahare NS, Pathophysiology [M], 6th ed, Pune, India, Nirali Prakashan,2009.[5]Titus AM, Revest P, Shortland P.The nervous system: basic science and clinical conditions[M], 2th ed, New Y ork, Churchill Livingstone, 2010.[6]Bernard JB, Nicole MG. Cognition, brain, and consciousness: introduction to cognitiveneuroscience [M], 2th ed, San Diego, California, Academic Press, 2010.[7]Hauser S. Harrison's neurology in clinical medicine [M], 2th ed, New Y ork, McGraw-Hill,2010.[8]Holdcroft A, Jaggar S. Core topics in pain [M], 2th ed, Cambridge, Cambridge UniversityPress, 2010.[9]George TG, Sanjeev MK. Alzheimer's: the latest assessment and treatment strategies [M], 1thed, Sudbury, Massachusetts, Jones & Bartlett Publishers, 2009.[10]A nna Zettergren. Genetics of Parkinson's disease, with focus on genes of relevance forinflammation and dopamine neuron development [M], 1th ed, Göteborg, Sweden, Chalmers Reproservice, 2010.[11]M ancuso M, Orsucci D, LoGerfo A, et al. Clinical features and pathogenesis of Alzheimer'sdisease: involvement of mitochondria and mitochondrial DNA [J]. Adv Exp Med Biol.2010;685: 34-44.[12]C aviness JN, Lue L, Adler CH, et al. Parkinson's disease dementia and potential therapeuticstrategies [J]. CNS Neurosci Ther. 2011;17: 32-44.第十七章内分泌系统的病理生理学[1]Antuna-Puente B, Feve B, Fellahi S, et al. Adipokines: The missing link between：insulinresistance and obesity [J]. Diabetes Metab, 2008,34(1):2-11.[2]Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the MetabolicSyndrome--an allostatic perspective[J]. Biochim Biophys Acta. 2010,1801(3):338-49.[3]Mehta NN, Krishnamoorthy P, Martin SS, et al. Usefulness of insulin resistance estimationand the metabolic syndrome in predicting coronary atherosclerosis in type 2 diabetes mellitus [J]. Am J Cardiol. 2011, 107(3):406-11.[4]廖二元，莫朝晖．内分泌学[M]．北京：人民卫生出版社，2007：1418-1424．[5]Nagao K, Yanagita T. Bioactive lipids in metabolic syndrome[J]. Progress in Lipid Research,2008,47(2):127-146.[6]Matsuzawa Y. The metabolic syndrome and adipocytokines [J]. FEBS Letters. 2006;580(12):2917-2921[7]Mathieu P, Pibarot P, Larose E, et al.Visceral obesity and the heart [J]. Int J Biochem CellBiol. 2008;40(5):821-836.[8]Calabro P, Yeh ET. Intra-abdominal adiposity, inflammation, and cardiovascular risk: newinsight into global cardiometabolic risk [J]. Curr Hypertens Rep. 2008 ,10(1):32-38.[9]Alberti KG, Eckel RH, Grundy SM, et al.Harmonizing the metabolic syndrome [J].Circulation. 2009; 120(16): 1640-1645.[10]Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome [J].Mediators Inflamm. 2010; 2010. pii: 289645.第十八章免疫系统的病理生理学[1]何韶衡，刘志刚. 基础过敏反应学[M]. 北京：科学出版社，2009[2]何韶衡. 实验过敏反应学[M]. 北京：科学出版社，2010[3]何维. 医学免疫学[M]. 第二版. 北京：人民卫生出版社，2010[4]金伯泉. 医学免疫学[M]. 第五版. 北京：人民卫生出版社，2008[5]康熙雄. 临床免疫学[M]. 北京. 人民卫生出版社，2010[6]殷凯生，毕志刚，何韶衡. 临床过敏反应学[M]. 北京：科学出版社，2011[7]Mark Peakman & Diego V ergani. Basic and clinical immunology [M], 2nd edition, ElsevierScience Health Science div,2009[8]Parslow TG, Stites DP, Terr AL, et al.Medical Immunology [M]. 10th. New Y ork:McGraw-Hill, 2000[9]Kasper DL, Braunwald E, Fauci AS, et al. Harrison's principles of internal medicine [M].17th. New Y ork: McGraw-Hill, 2008[10]Notarangelo LD, Fischer A, Geha RS, et al. Primary immunodeficiencies: 2009 update [J].J Allergy Clin Immunol, 2009, 124: 1161-1178。

部分SCI期刊版面费情况

杂志名称：CLIN NUCL MEDIF(2008):3.181学科专业：Nuclear medicine国家：USA彩图费用：First color 500 D, and add 150D every other colors Free pages,or any other publication fees.版面费计算：Zero + 彩图费杂志名称：INT J UROLIF(2008):0.982学科专业：Urology国家：Japan彩图费用：Free，don't charge color,pages,or any other publication fees.版面费计算：Zero对该杂志的感悟：专业杂志里的综合性杂志，发表专业相关的各类论文，IF不高，可以作为SCI文章的演练。

杂志名称：Hepato-GastroenterologyIF(2008):0.9学科专业：消化国家：希腊彩图费用：Free版面费计算：Free对该杂志的感悟：周期较快,IF不高,每年文章多,相对容易发表,适合菜鸟练手.杂志名称：CURR THER RES CLIN EIF(2008): 0.333学科专业：治疗学，包括临床和实验，偏重临床国家：美国彩图费用：未知版面费计算：$350 per page对该杂志的感悟：是CLIN THER（也是收费的，$500 per page，2008 IF 3.064）的姐妹篇，接受比较容易。

版面费很高，不过我作了免费申请，很快通过。

所以一分未花。

投稿到初次修回大约3月，在初次修回意见中可以基本确定能否接受。

再次投稿到确定接受2个月。

如果同意收费大约2月便能发表。

申请免费会延后发表时间，大约8个月。

可以根据自身情况选择是否交费。

杂志名称：J Biol ChemIF(2008): 5.52学科专业：biological chemistry国家：USA彩图费用：$300 for each illustration containing color版面费计算：$75 per journal page for the first nine pages. $150 per page starting with page ten。

运筹与管理相关SCI期刊

运筹与管理与本领域相关SCI期刊4ORACM Journal of Experimental Algorithms AlgorithmicaAnnals of Operations ResearchAsia-Pacific Journal of Operational ResearchCentral European Journal of Operations Research Computational Geometry: Theory and Applications Computational Optimization and Applications Computers & Industrial EngineeringComputers & Operations ResearchDiscrete Applied MathematicsDiscrete OptimizationDiscrete Mathematics & Theoretical Computer Science European Journal of Operational ResearchIIE TransactionsINFORMS Journal on ComputingInternational Journal of Computational Geometry and Applications International Transactions in Operational ResearchJournal of Discrete AlgorithmsJournal of HeuristicsJournal of the Operational Research SocietyJournal of Mathematical Modelling and AlgorithmsJournal of SchedulingLinear Algebra and its ApplicationsManagement ScienceMathematical and Computer ModellingMathematical Methods of Operations ResearchMathematical ProgrammingMathematics of Operations ResearchNaval Research LogisticsNetworksOmegaOperations ResearchOperations Research LettersOptimizationOptimization Methods and SoftwareSIAM Journal on OptimizationTransportation ScienceEI收录Journal of Algorithms and Computational TechnologyJournal of Applied Mathematics and Computing（EI 符合范围）Journal of Computational and Applied Mathematics（SCI难度不大）Journal of Systems Science and Systems Engineering（中国EI）Journal of the Operations Research Society of China（不被收录，中国刚办）Journal of Mathematical Modelling and Algorithms（不被收录，运筹优化的）The International Journal of Advanced Manufacturing Technology (SCI期刊，容易中，3个月审稿) International Journal of Innovative Computing Information and Control (SCI)International Journal of Systems Science (SCI)International Journal of Mathematics in Operational research (EI)International Journal of Mathematical Modelling and Numerical OptimisationPacific Journal of Optimization (华人多)Optimization Methods and Software (SCI期刊，据说容易中，2个月审稿，方向对口（小木虫说慢）)优化相关资料与网址收集Optimization and Operations Research:Operations Research: the science of better :/Science_of_Better/htdocs/prospect/index.aspOR directory (a bit out of date): http://www.math.tu-bs.de/mo/orlistings.htmlLP FAQs: /otc/Guide/faq/linear-programming-faq.htmlsome free software by Prof. John O. McClain:/faculty/mcclain/Software/Software.htmIFORS tutorial modules:/tutorial/benchmark for optimization software: /bench.htmlThe French OR Society /The European OR Society /The international federation of OR societies /The Canadian OR Society http://www.cors.ca/OR Society of the US /THE OR web page of Michael Trick /e-optimization /OR library of optimization instances OR-library/~mastjjb/jeb/info.htmlOperations Research Journals RSS ListOperations Research:Annals of Operations ResearchComputational Management ScienceComputers & Operations ResearchEuropean Journal of Operational ResearchINFORMS Journal on ComputingInterfacesInternational Transactions in Operational Research Journal of Optimization Theory and Applications Journal of the Operational Research Society Management ScienceMathematical ProgrammingMathematical Programming Computation Mathematics of Operations ResearchNetworksOmegaOperations ResearchOR SpectrumIndustrial Engineeing and Operations Management: Computers & Industrial Engineering International Journal of Production Economics International Journal of Production Research Manufacturing & Service Operations Management Naval Research LogisticsTransportation:Transportation Research Part B: MethodologicalTransportation Research Part E: Logistics and Transportation Review Transportation ScienceArtificial Intelligence:Advances in Engineering SoftwareApplied Soft ComputingDecision Support SystemsEngineering Applications of Artificial IntelligenceExpert Systems with Applications管理科学与运筹学(MS/OR)国际期刊最新权威排名首先声明：这份MS/OR国际期刊排名是完全根据2011年JCR（Journal Citation Reports）的Article Influence Score（AIS）而给出的。

2010年SCI收录机器人相关期刊

IEEE Transactions是公认的权威，绝大多数是所属领域的顶级期刊。

但是很多IEEE的标志性会议也是非常好的，比如IEEE ICRA（机器人领域顶级会议）、IEEE CDC（控制领域顶级会议）、ACC（控制领域顶级会议）等，这些会议并不比国内一些EI期刊好中。

截至到2009年2月SCI收录机器人学科期刊16种，其中2008年开始被SCI收录的机器人期刊3种，2007年开始被SCI收录的机器人期刊1种。

出版地为美国的机器人期刊4种，英国4种，荷兰4种，中国、西班牙、新加坡各1种。

中国出版的机器人期刊JOURNAL OF BIONIC ENGINEERING《仿生工程学报》为2008年5月被SCI收录。

2005-2008年SCI共收录至少有一位中国作者（不包括台湾）的机器人学科论文251篇，其中2008年85篇（0.0850 %），2007年64篇（0.0675 %），2006年53篇（0.0616 %），2005年49篇（0.0635 %）。

251篇论文包括学术论文206篇、会议论文42篇、社论2篇、更正1篇。

2005-2008年中国研究论文主要发表在以下几种SCI收录的机器人期刊上：JOURNAL OF BIONIC ENGINEERING《仿生工程学报》57篇，ROBOTICS AND COMPUTER-INTEGRATED MANUFACTURING 《机器人学与计算机集成制造》44篇，ROBOTICA 《机器人学》34篇，IEEE TRANSACTIONS ON ROBOTICS 《IEEE机器人学汇刊》32篇，JOURNAL OF INTELLIGENT & ROBOTIC SYSTEMS 《智能和机器人系统杂志》24篇，ROBOTICS AND AUTONOMOUS SYSTEMS 《机器人学和自控系统》15篇，INDUSTRIAL ROBOT-AN INTERNATIONAL JOURNAL 《工业机器人》14篇，ADVANCED ROBOTICS 《先进机器人学》13篇，INTERNATIONAL JOURNAL OF ROBOTICS RESEARCH 《国际机器人研究杂志》5篇。

敬来教授张敬来：教授,博士,硕士生导师

河南大学化学化工学院
翟翠萍副教授
招生专业：物理化学联系方式：zhaicuiping@
翟翠萍：副教授，博士，硕士生导师。先后承担本科生《物理化学》、《绿色化学与化工》
和《物理化学实验》等课程。发表SCI收录论文20余篇，出版教材一部。参与完成国家自然科学基金等项目4项，一直致力于用波谱学技术研究溶液或离子液体中化合物之间的相互作用及分子的微观结构。
研究方向：功能材料的结构与性能设计合成富氮、富氧等多官能团金属有机簇合物和聚合物，研究其结构及各种光、磁、电及热性能，揭示物质的结构与性质之间的相关性规律，以期获得光功能、磁功能或光-磁功能复合材料。
主要在研项目
1.新颖磁性功能材料的研究 2.新型杂化功能化合物的合理合成和性能研究
近期主要工作
2.2008年度河南省教育厅自然科学研究资助计划项目
低能电子引起DNA损伤的机理研究近期主要工作 1. Electronic spectra of the linear polyyne cations HC2 nH+ (n=2–8):An ab initio study The Journal of Chemical Physics 2009, 131, 144307 2. Electronic spectra of linear isoelectronic clusters C2 n1S and C2n1Cl (n=04): An ab initio study. Journal of Physical Chemistry A 2006, 110, 10324. 3.Electronic spectra of heteroatom-containing isoelectronic carton chains C2nS and C2nCl+ (n=1-5). The Journal of Chemical Physics. 2006, 124: 124319. 4. Electronic spectra of the linear magnesium-containing carbon chains MgC2nH (n = 1–5): A CASPT2 study Chemical Physics. 2009, 360, 27-31. 5. Ab initio studies of electronic spectra of the linear aluminum-bearing carbon chains AlC2nH (n = 1–5) Journal of molecular spectroscopy. 2009, 256, 242. 6. Theoretical strudies on structures and electronic spectra linear carbon chains C 2nH+(n=1-5) International Journal of Quantum Chemistry 2009,109:1116 7. Theoretical studies on the structures, electronic spectra and ionization energies of linear isoelectronic HC2n+1P and NC2nP (n=1-10). Journal of Molecular Structure: THEOCHEM. 2006, 761, 63. 8. Theoretical Study of Electronic Absorption Spectra of C3Cl and Its Ions. Journal of Molecular Structure: THEOCHEM. 2006, 773, 81-86. 9. Density functional theory study on lactides:Geometries,IR,NMR and electronic spectra Journal of Molecular Structure: THOCHEM 2007,816, 13. 10. CASPT2 studies on the electronic spectra of linear heteroatom-containing carbon chain anions C4O-, C4S- and C4Se-. Journal of Molecular Structure: THEOCHEM. 2006, 765:137.

SCI 投稿经历

今天收到邮件，我的一篇Journal of Applied Physics 论文已被接收，心情当时还是有点激动。

虽然这个杂志的影响因子不是很高，大概2.2左右吧，这也不是我的第一篇SCI论文，但回想这一年发文章的坎坎坷坷，以及亲身经历的四川大地震，心里还是有很多的感触。

这篇论文是我在2008年二月份完成的最初稿，于二月九号投到Physics Letters A上，在经历了Technical check，with editor，under review后，于三月二十号收到编辑的决定信，当时就傻了－拒稿！受打击了。

下面是编辑的信以及审稿意见，我想把它贴出来与虫友们分享，一方面我认为，通过看审稿人的意见，可以帮助大家更好地写作，提高自己的科研水平和能力，另一方面也是答谢小木虫上很多无私的虫友们，是他们将自己的投稿经历贴在网上，与大家分享，我想我没有理由不拿出来哈！同时，也希望小木虫的虫子们能继续发扬这种精神，大家同舟共济，共同提高！好了，废话说了一大堆，不说了，下面是Physics Letters A 的审稿意见：Ms. Ref. No.: ××××××Title: ×××××Physics Letters ADear professor ××,Reviewers' comments on your work have now been received. You will see that they are advising against publication of your work. Therefore I must reject it.For your guidance, I append the reviewers' comments below.Thank you for giving us the opportunity to consider your work.Yours sincerely,×××（编辑名）EditorPhysics Letters AReviewers' comments:Reviewer #2: ManuscriptThe authors present results of the 3D electron potential ofa gated quantum point contact in a AlGaAs/GaAs heterostructure.In contrast to earlier studies, it is now possible to derive thepotential landshape without any adjustable parameter. The resultsstill agree with earlier investigations using simpler phenomenologicalmodels. Since the used nextnano3 program is available since acouple of years, I wonder why this has not been done earlier.The authors emphasize an application of their results. Havingthe complete potential landshape might help, in the future,to better understand the quantized acoustoelectric current inSETSAW devices and to improve their performance.However, the authors do not show or even discuss how this canbe achieved. Therefore I believe that in the present form the paperis not suitable for publication.The authors should consider the following suggestions, questions,and remarks.1) Page 1, first paragraph'... due to the negatively applied gate voltage ...'. It is the SAWthat drives the electrons through the contact, not the gate voltage.Maybe replace this sentence by '..., depending on the applied gatevoltage'.2) Page 3, paragraph starting with 'Generally, the quantized ...''... with fixed x = 1050 nm and ...'. Skip the '.0'. One could addthat this is exactly at the center of the device.3) At the end of the same paragraph is '... once the bias is below ...'Should this not be the gate instead of the bias voltage?4) Page 4, paragraph starting with 'As we know, in the ...''... To be different from previous calculations ...' replace by'... In contrast to previous calculations ...'.5) The strongly different behaviour above and below the pinch-offvoltage is not obvious for the non-experts. All curves look moreor less the same. One could, for example, add another figure, orinsert, to show the potential height versus gate voltage.6) How do these theoretical results of potential height versus gatevoltage compare with experiments? There exists at least onereport to determine the potential height of quantum-point contactsbelow pinch-off as function of gate voltage (Gloos et al., Phys.Rev. B 73, 125326 (2006)). Possibly, one could also compare thepresent data with 3D simulations of quantum dots (Vasileska et al., Semicond. Sci. Technol. 13, A37 (1998)).7) Figure 1，It would be better to mark the distance between the two metal gatesas the relevant parameter, and not the size of one gate.8) Figure 3The numbering of the two density axes looks rather odd. Could it notbe done with integers, like 3 instead of 3.2 or 3.0?9) Figure 5 (b)Should there not be an anomaly or kink in the potential near the Fermilevel?在仔细读了审稿人的意见后，我觉得审稿人提出的5）和6)意见非常好，后来自己想想，决定把文章来个彻底的修改。

前辈的投稿经历

作者: menggang201 发布日期: 2009-03-28【期刊名称】：Materials Science and engineering A【投稿日期】：2008.10.2【返回意见日期】：2009.1.14（Major Revision）【修改稿投出日期】：2009.3.2（过年）【最终接受日期】：2009.3.12【投稿感受和体会】：偶的第一篇一篇SCI，这个杂志在金属领域是比较好的。

其实说不上时间长，最大的感受是写文章一定要精益求精，抱着绝对认真的态度，老外真的是很严谨的，细致到文中参考文献出现的顺序出错都能看出来，写SCI 的过程是对自己严格历练的过程，第一篇写的很困难，接下来就容易些了，第二篇也是投的这个杂志，基本没改，3月20号就接受了。

感慨颇多，三年硕士还是小有收获的。

马上就要走上工作岗位，希望能将所学用于实践，在此与各位虫友共勉！作者: ddup885 发布日期: 2009-03-30【期刊名称】：International Journal of CFD【投稿日期】：7 August 2008【返回意见日期】：5 Nov 2008【最终接受日期】：2 Dec 2008【投稿感受和体会】：这是本人的第一篇SCI也是目前仅有的一篇。

动笔写了一个月，中途又投了其它两个杂志均被以不符合杂志内容拒稿，最终选定这个杂志。

编辑非常认真，推荐审稿人就推荐了三次，直到一个中国人都没有了才可以。

写过一次催稿信，编辑说我推荐的六个审稿人有四个拒绝审稿，一个已经回来意见了，在等另一个。

没过几天，审稿意见就回来了，一个审稿人提了七条意见，另一个完全通过，现在想想好感激第二个审稿人呀，给了我继续下去的信心，虽然我不知道他是谁，只是从其它相关期刊上找的编委。

对第一个审稿人的意见进行了认真的回答，文章本身基本没有什么改动。

修改了一次就成功了，编辑要我加一些该杂志的参考文献，之后就是版权协议等事项了。

只是现在的状态还是ready for publication 呀，真是祈祷赶快发表呀。

SCI、EI等收录及论文他引情况的检索技巧及常见问题分析

每周讲座证明的类型science收录及引用证明eiengineeringvillage收录人大复印报刊资料全文数据库收录每周讲座sciexpanded科学引文索引sciencecitationindex简称sci由美国科学信息所isi1961年创办并编物学等广泛的学科领域其中以生命科学及医学化学物理所占比例最大收录范围是当年国际上的重要期刊
每周讲座
证明的类型
1. 2. 3. 1. 2. 3. 4. 英文文献 Web of science 收录及引用证明 EI（Engineering Village ）收录 Medline(PubMed)收录中文文献中国科学引文数据库（CSCD）收录及引用中文社会科学引文索引（CSSCI）收录及引用中国知网（CNKI）的引文索引人大复印报刊资料全文数据库收录
Engineering Village 简介：《Engineering Village》是由美国工程信息公司在英特网上提供的网络数据库，它的核心产品《Engineering Index》（工程索引）闻名于世。Ei Compendex Web数据库除了收录1969年以来的Ei Compendex数据（每年收录2600余种工程期刊、会议录和科技报告）以外，还包括1990年以来的Ei PageOne数据（在Ei Compendex的2600种期刊基础上扩大收录范围，每年收录5600种工程期刊、会议录和科技报告）。
每周讲座
Web of science 引用检索结果标题: Metal-Organic Frameworks with Functional Pores for Recognition of Small Molecules 作者: Chen Banglin; Xiang Shengchang; Qian Guodong 来源出版物: ACCOUNTS OF CHEMICAL RESEARCH 卷: 43 期: 8 页: 1115-1124 DOI: 10.1021/ar100023y 出版年: AUG 2010

SCI版面费问题

6、杂志名称：JOURNAL OF BIOLOGICAL CHEMISTRY
IF(2008): 5.52
学科专业：biological chemistry
国家：USA
彩图费用：$300 for each illustration containing color
版面费计算：$75 per journal page for the first nine pages.
链接：

Author Instructions and Mandatory Submission Form are available here:
/authorinstruct.htm
All manuscripts should be submitted to:
前4页免费，之后每页99美元
IF(2008):3.181
链接：/science/journal/00411345
3、杂志名称：INTERNATIONAL JOURNAL OF UROLOGY
IF(2008):0.982
学科专业：Urology
国家：Japan
对两个杂志的感悟：
对国人好像都比较友好，相对容易接受。
OPHTHAL RES周期短，审稿时间1个月，确定接受到PROOF6个月，网络见刊1个月，正式书面见刊3个月
OPHTHALMOLOGICA杂志超慢，投稿到修回3个月，确定接受到PROOF遥遥无期，我投稿的一篇2007年底接受，目前该杂志2009年全年的杂志仅剩余最后两期，今年发表已经基本无望，整整两年时间，郁闷。
出版地：丹麦出版Monthly
栏目：Original Article ;Case Report ;Minireview ;Brief Communication ;Letter to the Editor;Personal Viewpoint Forum ;Editorial ;What's New - What's Hot ;Book Review ;Meeting Report;SPECIAL ARTICLES

分析化学类杂志简介

9
收载内容
重点关于分离和纯化生物系统中化合物使用的制备分系统中化合物使用的制备分离相关技术(包括色谱分析、离相关技术(包括色谱分析、电泳、亲和分离等) 电泳、亲和分离等)。
附注
•药代方面的文章比较药代方面方面的文章比较容易发表。当然，容易发表。当然，其他色谱方面的文章也能被发表。能被发表。
1
6.546 2009
属于分析化学中的顶级属于分析化学中的顶级杂志
TrAc中的文章是对分析化学的新中的文章是对分析化学的新中的文章是对分析化学的发展的简要概述。发展的简要概述。 • 帮助分析化学家和其他分析技术使用人员探索和跟踪分析化学的最新研究领域。最新研究领域。
附注
影响因子不是太高，影响因子不是太高，但是一级杂志，要求很高，级杂志，要求很高，投稿比较困难,审稿速度较慢，较困难,审稿速度较慢，6-12 周。不是一流水平，不是一流水平，这类杂志不要想了，几乎是约稿约稿。要想了，几乎是约稿。
1.317
2009
杂志简介投稿命中率投稿命中率80%！
• 审稿速度较慢，不过没有什么大审稿速度较慢，问题的话一般让你改改文章中的错误就直接接受了。错误就直接接受了。 • 提供最快速最近时期内高效率提供最快速最近时期内最快速, 的报道。的报道。
6
6.分析化学
【英文名]Chinese journal 英文名 of analytical chemistry 国家】【国家】中国出版社】【出版社】Chinese Electronic Periodical 【ISSN】0253-3820 】出版次数】全年12 12期【出版次数】全年12期 1999年SCI扩展版收载年扩展版收载

谈SCI、EI、ISTP 三大索引收录号的检索

参考文献
[1] 任翠娟. SCI 及其网络版的检索方法与技巧[ J] . 图书馆学研究, 2003, ( 1) .
[2] 吕淑萍, 谢桂平. 基于 I SI 检索平台的引文检索补遗[ J] . 情报科学, 2007( 11) .
[3] 马桂君, 庞十周. SCI 文献的检索技巧及检索词的输入规则[ J] . 编辑之友, 2006, ( 4) .
谈SCI、EI、ISTP 三大索引收录号的检索
田文利, 于振磊, 武继芬, 50353)
摘要从检索路径、检索方式和符号识别等方面对 SCI、EI、ISTP 三大索引收录号的检索进行了详细说明, 并对 ISI Web of Knowledg 的新旧平台下 SCI 和 ISTP 的检索注意事项作了补充强调。
关键词科学引文索引( SCI) 工程索引(EI) 科学技术会议录索引( ISTP) 检索收录号
科学引文索引 ( 简称 SCI) 、工程索引( 简称 EI ) 、科学技术会议录索引 ( 简称IST P ) 是世界公认的著名的三大索引, 被三大索引收录与否是衡量一篇论文学术水平高低的重要尺度。自 2008 年始, 各高校和科研院所在统计本单位职工所发表论文被三大索引收录情况时, 相继提出了论文在三大索引中的收录号问题。天天论文网是一个专业的学术馆式高素质论文推介平台/论文集中发表平台，天天论文网十年耕耘，和多家杂志社开通论文直通车，提高了工作效率，减少环节流程，论文能够尽快获得审稿结果，从而加快了论文发表到合适的学术期刊上进程！拥有专业的学术团队，凝聚了一批行业内资深、有活力的成员。本站工作人员拥有硕士以上学历，中级以上职称多名。另外聘几大高校的教授和博导，拥有坚强的学术交流后盾。从业人员均曾在各大期刊发表了大量的学术论文，在各自专业领域上有着出色的表现以及丰富的学术功底，他们有着高水准的审稿水平和高层次的学术渠道，更具魅力的是他们的创造力和奉献精神；工作中天天论文网和出版社也有合作，需要出书的，可以联系我们，单书单号，国家级出版社，费用优惠！也可以代办专利申请科研基金挂名等事务。天天论文网官方论文投稿杂志社直通车信箱：zzsztc@ 收录号能体现出该篇论文被收录情况的针对性和唯一性, 也具有易于统计和管理的特点, 因而被逐渐重视。但通过检索中国学术期刊和中文科技期刊两大中文数据库, 却均未发现与收录号检索相关的文献。下面笔者就谈一谈近年来对这三大索引收录号的检索心得和检索技巧, 以期对大家有所帮助。相对于 SCI 和 ISTP, EI 的收录号检索相对简单并易于识别, 而 SCI 和 ISTP 的收录号检索就相对复杂和较难识别了。1 EI 收录号的检索1. 1 EI 收录文章检索首先我们先进到 EI 数据库( Web 版) 的检索界面, 在检索论文的被收录情况时一般需要输入作者名( Author) 和作者机构名( Author aff iliat ion) , 并将年代加以限制, 为了使检索结果更为精确, 也可找杜老师论文QQ2035204840再复合一个题名( T itle) 检索, 然后点击 search 进行检索。在得到检索结果后,可进行相应的筛选, 选择出所需的条目。每一条目由文章篇名, 作者机构、来源刊物名称、年、卷、期、起止页码组成。1. 2 EI 收录号检索点击第一个单词 Abstract 可以得到该篇文章的详细信息, 如国际连续出版物编号( ISSN ) 、出版商( Publisher) 、文摘( Abstract ) 、主题词( Ei controlled terms) 和分类号( Classificat ion Code) 等。但这里面却不包含收录号, 要获取收录号还需要点击 Detailed, 这里面给出的信息更为详尽, 除以上项目外还有第一行的如:Accession number: 083211432051 和最后一行的如 DOI: 10. 1007/ 978- 3- 540- 69733- 6 7两个著录项目, 其中 DOI 是 Digital Object Ident if ier 的缩写, 表示数字对象唯一标志符,Accession number 即为我们所需要的收录号,它是由 12 位阿拉伯数字组成。1. 3 检索 EI 注意事项在 EI 收录号的检索中应该注意分清每个著录项目, 尤其是一些由字母和数字组成的代号, 如 DOI, 搞清楚它的含义, 以免与所需要的收录号混淆。2 SCI 和 IST P 中收录号的检索SCI/ IST P 由同一家数据商经营, 设在同一个检索平台 ISI Web of Knowledge 上, 所以具有完全相同的检索界面。下面以SCI 为例进行检索:2. 1 选择 SCI 和 IST P 检索首先进入到 ISI Web of Knowledge 检索平台, 选择进入 Web of Science 界面, 自 2008 年年底该平台进行改版后, SCI 和 IST P 均在该界面下进行检索, 并出现了中文检索界面, 在引文数据库项目下, 第一个 Science citation index为SCI 检索, 第二个Conference proceeding citat ion index 即为 IST P 检索, 可勾选进行相应的检索。2. 2 SCI 和 IST P 文章检索在检索框中输入相关的检索信息, 比如作者= Qin MH AND 地址= Shandong instlight ind, 注意, 这里的地址是指作者所在机构, 必须输入缩写词方可进一步查询, 这就要求检索者必须熟悉并正确拼写相关机构的英文名称及缩写词, 否则难以得到准确的结果。然后点击 SEARCH , 经过著者途径或主题途径等检索并筛选出所需的条目后, 点击文章篇名即可显示更详细的信息, 如文章篇名、作者机构、来源刊物名称、年、卷、期、起止页码、文章摘要等, 在这个页面下有一个如 IDS Number:266JS 的号码, 往往会使人误以为这就是论文的收录号, 其实不然, IDS Number 实际上是论文所在期刊的期刊号。要获取收录号职称相关事务咨询QQ258347976首先需要点击页面下方的输出记录部分, 选择全记录格式, 右面的保存项中选择保存为 HTML 格式, 然后点击保存 ,出现处理记录的界面, 再点击保存 , 可保存到自选的目录文件夹里。2. 3 SCI 和 IST P 收录号检索要获取收录号首先需要点击页面下方的输出记录部分, 选择全记录格式, 右面的保存项中选择保存为 HTML 格式, 然后点击保存 ,出现处理、记录的界面, 再点击保存 , 可保存到自选的目录文件夹里。其次, 打开保存的 HTML 格式网页, 或者下载完毕后直接打开保存的文件, 这时得到的是格式不同但同样包含文章篇名, 作者机构、来源刊物名称等各种详细信息的文摘条目, 但在最后增加了一个由 15 位阿拉伯数字组成的如U T ISI: 000250604100008 的记录格式, 注意此号码即为我们所需要的 SCI 收录号, 获取 IST P的方法与此完全相同。2. 4 检索 SCI、IST P 注意事项在这里还应提到的是, 在旧版的 ISI Webof K now ledge 数据库中, 因为 SCI 与 IST P 不在同一个检索界面下进行检索, ISTP 是通过 ISIProceeding 检索界面进行检索, 收录号的标识也有所区别, SCI 用UT ISI 来代表, 而 ISTP 用U T IST P 来代表, 但现在统一用 U T ISI 来表示, 只是需要注意在检索时要选择对应的数据库进行检索。综上所述, SCI、EI、ISTP 三大索引的收录号检索可归纳为两个要领: 一为牢记检索路径,二为注意符号的识别。掌握好这两个要点, 再加上多次的练习实践, 就会由难者不会转变为会者不难并熟练掌握了。

SCI收录关于食品微生物发酵刊物

SCI收录关于微生物发酵刊物Abbreviated Journal Title Impact FactorADV APPL MICROBIOL 1.821ADV MICROB PHYSIOL 4.9ANN MICROBIOL 0.315ANNU REV MICROBIOL 14.362ANTIMICROB AGENTS CH 4.39APPL BIOCHEM MICRO+ 0.51APPL ENVIRON MICROB 4.004APPL MICROBIOL BIOT 2.475AQUA T MICROB ECOL 2.385ARCH MICROBIOL 1.838BIOMED MICRODEVICES 3.073BIOMICROFLUIDICSBMC MICROBIOL 2.982BRAZ J MICROBIOL 0.339CAN J MICROBIOL 1.286CELL HOST MICROBECELL MICROBIOL 5.293CLIN HEMORHEOL MICRO 0.977CLIN MICROBIOL INFEC 2.98CLIN MICROBIOL REV 15.764COMP IMMUNOL MICROB 0.81CRIT REV MICROBIOL 3.368CURR MICROBIOL 1.167CURR OPIN MICROBIOL 7.654CURR TOP MICROBIOL 4.411ENVIRON MICROBIOL 4.929ENZYME MICROB TECH 1.969EUR J CLIN MICROBIOL 2.309FEMS MICROBIOL ECOL 3.039FEMS MICROBIOL LETT 2.274FEMS MICROBIOL REV 9.25FOLIA MICROBIOL 0.989FOOD MICROBIOL 2.039FUTURE MICROBIOL 0.645GEOMICROBIOL J 1.655IEE P-MICROW ANTEN P 0.489IEEE MICRO 1.701IEEE MICROW MAG 1.18IEEE MICROW WIREL CO 1.725IEEE T MICROW THEORY 1.907IET MICROW ANTENNA PINT J ANTIMICROB AG 2.338 INT J FOOD MICROBIOL 2.581 INT J MED MICROBIOL 2.524 INT J RF MICROW C E 0.291INT MICROBIOL 2.617J ANTIMICROB CHEMOTH 4.038 J APPL MICROBIOL 2.501J BASIC MICROB 0.991J CLIN MICROBIOL 3.708J ELECTRON MICROSC 1.172J EUKARYOT MICROBIOL 1.525 J GEN APPL MICROBIOL 0.925 J IND MICROBIOL BIOT 1.681J MED MICROBIOL 2.091J MICROBIOL 2.05J MICROBIOL BIOTECHN 2.062 J MICROBIOL METH 2.153J MICROELECTROMECH S 1.964 J MICROENCAPSUL 1.168J MICROLITH MICROFAB 0.986 J MICROMECH MICROENG 1.93 J MICRO-NANOLITH MEMJ MICROPALAEONTOL 0.258J MICROSC-OXFORD 1.565J MOL MICROB BIOTECH 2.588 J RECONSTR MICROSURG 0.722 LETT APPL MICROBIOL 1.623 MAR MICROPALEONTOL 1.505 MED MICROBIOL IMMUN 1.537 METHOD MICROBIOL 0.6 MICRO 0.172MICRO NANO LETT 0.63 MICROB CELL FACT 0.547 MICROB DRUG RESIST 1.543 MICROB ECOL 2.558MICROB PA THOGENESIS 2.064 MICROBES INFECT 2.523 MICROBIOL IMMUNOL 1.295 MICROBIOL MOL BIOL R 14.629 MICROBIOL RES 1.535 MICROBIOLOGY+ 0.597 MICROBIOL-SGM 3.11 MICROCHEM J 1.8 MICROCHIM ACTA 1.959MICROCIRCULA TION 2.955MICROELECTRON ENG 1.503MICROELECTRON INT 0.571MICROELECTRON J 0.609MICROELECTRON RELIAB 1.011MICROFLUID NANOFLUID 2.241MICROGRA VITY SCI TEC 0.467MICROLITHOGR WORLD 0.29MICRON 1.651MICROPALEONTOLOGY 0.647MICROPOR MESOPOR MA T 2.21MICROPROCESS MICROSY 0.524MICROSC MICROANAL 1.941MICROSC RES TECHNIQ 1.644MICROSCALE THERM ENG 1.417MICROSURG 1.07MICROSYST TECHNOL 0.912MICROV ASC RES 2.365MICROW OPT TECHN LET 0.631MICROWA VE J 0.191MICROWA VES RF 0.054MOL MICROBIOL 5.462MOL PLANT MICROBE IN 4.275NANOSC MICROSC THERM 0.538NA T REV MICROBIOL 14.959NEW MICROBIOL 0.956ORAL MICROBIOL IMMUN 1.854RES MICROBIOL 2.219REV MED MICROBIOL 1SUPERLA TTICE MICROST 1.344SYST APPL MICROBIOL 2.514TRENDS MICROBIOL 7.618ULTRAMICROSCOPY 1.996VET MICROBIOL 2.01WORLD J MICROB BIOT 0.745相对比较容易发表的杂志：J Clin Microbiol2009IF：4.162杂志国家：United States2008收稿量：732发表周期：Monthly投稿网站：https:///ASM2/CALogon.jsp. 审稿周期：30天投稿经验总结：主要集中在微生物的etiological agents, diagnosis and epidemiology。

SCI论文被接收心得

SCI论文被接收心得第一篇：杂志：Talanta（２.８分）RecEived at Editorial Office: 18-SEP-2007Article revised: 15-JAN-2008Article accepted for publication: 18-JAN-2008专业：生物分析化学类说起这篇文章，可是让我痛苦了一整年，实验很多，做的很辛苦，数据相对繁多，由于这是我第一篇文章，写作方面也是摸石头过河，逐句的模仿．为了写这篇文章，我仔细研读了该领域的大约１００篇文献，对别人写的好的句子，类似的句子都做了标记，在写作的过程中想起要表达什么意思的时候马上随时翻阅，这样下来，每天写一小段，有时候甚至每天就写那么几小句，大约一个月后，我发现一篇包含abstract,intrduction,experiment,results and discussion初稿居然完成了．初稿完成后，放了大约个把星期不管，接着做其他的实验，待一个星期过后再来研读，发现文章写的错误百出，句子连贯性，逻辑性，以及整篇文章的通读性都很差，于是又是仔细研读别人的论文，学习再学习，每天读一点，回头看看自己的文章，再改一点，又是将近个把月，一篇有模有样的初稿出现了，这时候我迫不极待的想把文章投出去了，于是放了两三天后，写了个cover letter,花了一晚上时间（想必应该也有人花一整个晚上在Elsevier投稿系统上的痛苦经历吧），把稿件投向了一个本领域的分析杂志．稿件投出去大概半个月，收到了主编的信，主编认为我能回答他的问题，以及按他的意见修改就可能出版．可能是经验欠缺，我在收到信后的一个星期，就把修改稿返回了过去，对其中的提到的不足和问题我只是在文章中引用了其他一些文献和做了自己的说明，显然，这样的举动在主编和认为是很不认真的，过了一个月后，收到了Final Decision，那就是拒绝了．Dear ***,On behalf of the editor handling your manuscript, I am writing to you in reference to your manuscript entitled:************I regret to have to inform you that your manuscript is not suitable for publication in ***. This decision has been reached in light of the comments made by the referees. The detailed remarks are appended below.Reviewers’ comments:Reviewer 1: ************* seemed to contain sufficient material for publication purpose. However, unfortunately, the authors did not address sufficiently what are the main advantages of this particular detection technique over previously reported ones.*************Overall, the English language proved to be insufficient for publication purpose and needs to be revised. Specific care should be taken with regards to prepositions since it can alter the meaning of a statementEditor:Unfortunately, the reviewer has recommended against publication of this work in ***. In examining the rev iewer’s specific comments, I note that some of the comments mirror those that I made when the manuscript was initially submitted. In particular, the reviewer indicates that the authors have still not made a convincing case for the advantages of the proposed method over earlier techniques. Given these considerations, I must regrettably recommend rejection of this manuscript.就因为没有用心写出文章的优点来，就这样被毙掉了，感到非常痛心，教训深刻！接下来，我又挑选了一个杂志，我自认为应该很容易中，因为我在那个杂志上看到有类似的文章，且我自认为内容还不如我的好．可是两本杂志属于不同的出版集团，引用文献的格式完全不同，又痛苦的花了一个晚上把文献格式改了过来，这种工作就和做针线活差不多，睁着眼睛在看，你不能急，一急就郁闷的不得了．于是乎，又是一翻上传的痛苦经历，可是，不到两天，不幸又降临了，居然认为我的稿件不适合该杂志，说白了，就是不想要嘛．Dear Dr***,I am writing to you on behalf of Editor ****.We regret to inform you that **** is unable to accept your manuscript*******, Manuscript No. ABC-00938-2007 for publication in *****.In view of the limited number of pages available to us each year to cover the entire field of analytical and bioanalytical chemistry, its instrumental advances and its wide range of applications, we can only publish a selection of the papers submitted to our journal.We are sorry not to be able to send you better news.这个时候，什么情绪都有了，有时候想，是不是自己的工作还没有够的上档次？是不是文章真的写的很差，因为还没有接收过ＳＣＩ论文，所以这个时候的自信心真的是非常的差，后来干脆把文章晾在了一边．心情平静下来了又想，花了这么多心思做的东西，是不可能放弃的，况且当初在选这个题目的时候就认为这个工作还是有一定意思和意义的．于是，我根据之前审稿人的意思，又补充了一些实验，在写作上也丰富了一些．过了一个多月，我又开始了新的冲击．这一次，显然，努力得到回报了．Dear professor ***,We have received expert review of your manuscript. You will see that revision of your manuscript is advised, and suggestions are offered for improving the manuscript and it’s impact. If you are prepared to undertake the work required, I would be pleased to consider the paper for publication in Talanta.For your guidance, reviewers’ comments are appended below. Reviewers’ comments:Overall, this is a paper that deserves to be published, but requires revision.(有这一句就够了，当时心情超好，无法形容）象下面这样的意见，也是非常中肯的，感谢审稿人，感谢编辑，感谢ＣＣＴＶ！General comments:The English used in this paper requires major revision. I do not underestimate the challenge of writing a scientific paper in a language that is not the native tongue. However, the science is currently being complicated by the grammar of the paper. In particular, single/plural conflicts and changes of (and inappropriate use of) tenses (see especially section 2.5 where the middle third of the text switches to the present tense). Improving the paper in this way would ensure that the reader can focus upon the science1. The discussions throughout the manuscript is superficial, thus thorough and comprehensive discussions are required in the section of Results and Discussion.2. Conclusion should not be a duplication of the Abstract.当然，也提出了其他的不少意见，这次我可是对待的相当认真，其中有一条审稿意见我不太明白，为此我在某专业论文上发贴和别人讨论了一个多星期．修改了个把月，上传，第三天，刷新邮件，收到来信如下：Dear professor ***,I am pleased to confirm that your paper ****** has been accepted for publication in Talanta.With kind regards,接下来讲讲我的第二篇Journal title: Electrochemistry Communications（3.48分）Received at Editorial Office: 23-DEC-2007Article revised: 29-JAN-2008Article accepted for publication: 30-JAN-2008实际上，在第一篇文章的辗转经历中，第二篇文章的实验已经在进行并且写作了，有了第一次的经历，第二篇文章在写作上显然轻松了许多，考虑到还有不多久快要放寒假，因此我在考虑把稿件要么投一个审稿周期长点的杂志，那么在假期中就不需要为稿件操心了，要么就投一个快点的杂志，干脆在放假前就搞定，最后经过权衡，我选择了后者．2007年12月18日晚，稿件上传，１９日，收到回信，还以为是拒了，吓一跳，原来是文章长了，要缩短．Electrochemistry CommunicationsDear professor ***,This paper is too long for Electrochemistry Communications which aims to publish short, urgent communications (see Guide for Authors).Please either submit it elsewhere as a full paper or shorten it to Communication Length and resubmit.For Communication Length please observe the following formula: Total number of words + 200 x (No of figures + No of tables) 3000. Your paper currently contains 2929 words and 4 figures. According to the formula above, this is the equivalent of 3729 words, which is too long for this journal.Yours sincerely,R. ComptonEditor in ChiefElectrochemistry CommunicationsElectrochemistry CommunicationsPhysical and Theoretical Chemistry LaboratorySouth Parks RoadOxfordOX1 3QZUK按照要求，仔仔细细的缩短，又顺便修改润色了一翻，花了一个星期，在西方的圣诞节的前一天，我把稿件发了出去，当时西方正在放假，可想而知，稿件躺在里面毫无动静，大约到了元月８日，我觉得也应该放假归来了吧，可怎么还没有给我的稿件那怕是分配一个稿件号呢？因为这个杂志向来速度是很快的，通常一个月内完成从稿件接受到接收的过程．于是，我写了封信给编辑：Dear professor R. ComptonWe have shorten our manuscript entitled ********* to communication length and resubmitted it to Electrochemistry Communications on 23 December 2007, but have not, as yet, receive the assigned manuscript number. We fear that the manuscript may have been lost and should be grateful if you would let us know whether or not you have received it. If not, we will send our manuscript again. Thank you in advance for your help.Best regards,第二天，回复了，并且马上分配了稿件号，果然上班了，可能是假期归来，身心疲惫吧．做编辑也不容易．这样半个多月的某天早晨，已经放假了，可是大雪封路，回不了家啊，干脆在床上睡懒觉，师姐的一个电话把我叫醒了，说让我查查邮件，文章要修改，１０天之内完成．打开电脑，一个喜庆的邮件展现在我面前．Electrochemistry CommunicationsDear professor ***,We will be pleased to accept your manuscript after revision in the light of the enclosed referee’s comments provided they can be attend ed towithin 10 days.Please submit a letter fully detailing your response to each point raised by the referee along with your revised manuscript.Yours sincerely,R. ComptonEditor in ChiefElectrochemistry CommunicationsReviewers’ comments:Reviewer #1:The authors of this manuscript reported a new application of electrochemiluminescence (ECL) method in assaying telomerase activity. In this work, the magnetic beads-based TRAP-ECL assay was found to be a rapid and very sensitive (c.a. 100 fold increase in sensitivity) method to detect telomerase activity in tumor cells, as compared with the conventional TRAP method. This is an important work for the developed novel TRAP-ECL assay may become a first line assay for clinical diagnosis and prognosis of cancer. Additionally, the paper was organized and presented well, and literatures were cited adequately. I recommend publication after minor revisions.Additional Comments:1. A previous important work by Miao and Bard (Anal. Chem. 2004, 76, 5379-5386) on magnetic beads-based ECL for DNA detection should becited.2. The words ?about 100 fold lower than that ? (page 6, line2) should be changed to ?about 100 fold higher than that ?.审稿人很认同我的工作，小小的修改，哪要１０天，个把小时就可以完成啊．就这样很快的完成了修改，第二天就接到了录用通知．心里那是相当的高兴的．小小的总结：１英文写作：两篇文章全部是由我一个人操刀写成，期间除了第一篇文章找一位老师改了几个句子，能够得到发表，说明最终英文的写作还是达标了．我的心得那就是模仿，没错，看别人怎么写，再套用，说实话，我们自己写的句子有几句能信的过呢？说到模仿，那也必须阅读过大量的文献，当你写作卡住的时候，你得想得到我在哪里看到过类似的句子才行．我前后看过的文献大概有２００篇左右．２投稿杂志的选择：从我的经历来看，显然并不能以自己的主观想法为信条，有时候你认为好的，适合的杂志显然并不适合你，当然，这不一定是你的文章不适合某某杂志，更可信的理由是你的稿件恰好不适合某个审稿人的胃口．３非常认真的对待审稿人的意见：尽可能详细的回答审稿人的问题，那怕是你自己认为都写的有点罗嗦了都没关系．审稿人是有感情的嘛．。

IF值的含义

影响因子一、什么是IF？影响因子（impact factor, IF）是一个国际上通行的期刊评价指标，由E.加菲尓德于1972年提出。

由于它是一个相对统计量，克服大小期刊由于载文量不同所带来的偏差，所以可相对公平地评价和处理各类期刊。

二、IF是怎样计算出来的哪？具体算法是将某期刊前两年发表的论文在统计当年的被引用总次数除以该期刊在前两年内发表的论文总数。

公式：影响因子(Impact Factor)=（该刊前两年发表论文在统计当年被引用的总次数）/ （该刊前两年发表论文总数）举例：某期刊2008年影响因子的计算：本刊2007年的文章在2008年的被引次数：96 本刊2007年的发文量：374 本刊2006年的文章在2008年的被引次数：256 本刊2006年的发文量：308 本刊2006-2007的文章在2008年的被引次数总计：352 本刊2006-2007年的发文量总计：682 本刊2008年的影响因子：0.5161 = 352÷682 三、IF的意义？该指标是相对统计值，一般来说，影响因子越大，其学术影响力和作用也越大。

从20世纪80年代，期刊把影响因子作为期刊所追求的主要目标，甚至是期刊生存唯一的目标，并有许多人把它赋予了更多的内涵。

但影响因子仅是评估期刊的重要参数之一，并不是对论文质量、期刊质量进行有效评价的唯一标准。

目前还没有一个完善的分析期刊学术质量及论文学术水平的评价体系，单独用影响因子评价期刊和论文的质量，某种意义上是对期刊、作者、论文水平评价的一种误导。

四、有关IF的思考正确引用相关参考文献是对前人、他人劳动成果的尊重，是遵守实事求是的原则和严谨的科学态度。

但应该引起专家、作者极大关注的是，一方面是有的期刊为了达到提高影响因子的目的，在参考文献条数的来源上大做文章，有的研究性论文甚至只有寥寥几条参考文献；另一方面，虽然专家在期刊上发表了大量的论文，但被引用率却比较低，就连专家本人也不去引用，这只能说明其论文学术水平和在本学科专业的影响力还不够。

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

Rank AbbreviatedJournalTitle ISSN Total Cites Impact5-Year Immediacy Articles Cited EigenfactorFactor Impact Index Half-life Score 序号期刊名缩写ISSN号总被引次数影响因子5年期影响因子即年指数论文数量半衰期特征因子1AAPG BULL0149-14234588 1.364 1.630.35368>10.00.00685 2AAPS PHARMSCITECH1530-99321078 1.4450.0916740.00355 3AATCC REV1532-88132520.3520.4650.0914450.00141 4ABDOM IMAGING0942-89252122 1.485 1.6230.387124 6.60.00516 5ABH MATH SEM HAMBURG0025-58583180.0860.15607>10.00.00035 6ABSTR APPL ANAL1085-33752830.6440.53360 4.90.0021 7ACAD EMERG MED1069-65634406 2.46 2.4880.433187 5.70.01618 8ACAD MED1040-24465422 1.867 2.337 6.80.02075 9ACAD RADIOL1076-63323027 2.021 2.0060.40716750.01069 10ACCOUNTS CHEM RES0001-48422625212.17615.403 2.6831677.70.0727 11ACCREDIT QUAL ASSUR0949-17754730.7810.6020.27580 4.60.00118 12ACI MATER J0889-325X16720.5680.8810.08372>10.00.00338 13ACI STRUCT J0889-324119290.895 1.1440.167729.70.00714 14ACM COMPUT SURV0360-030032739.9214.672 2.167129.10.00648 15ACM SIGPLAN NOTICES0362-13408460.1630.2190.0132288.90.00199 16ACM T COMPUT LOG1529-3785374 2.7660.2762940.00294 17ACM T COMPUT SYST0734-******** 2.391 3.6490.510>10.00.00159 18ACM T DATABASE SYST0362-59151404 1.613 3.6510.07427>10.00.00401 19ACM T DES AUTOMAT EL1084-43094070.848 1.3030.09861 5.40.00159 20ACM T GRAPHIC0730-******** 3.383 4.9970.15107 4.70.02629 21ACM T INFORM SYST1046-81881455 1.472 6.3060.174237.70.00334 22ACM T MATH SOFTWARE0098-35002111 2.197 3.3610.52638>10.00.00581 23ACM T MODEL COMPUT S1049-3301437 1.0290.0520>10.00.001 24ACM T MULTIM COMPUT1551-6857155 2.4650.03727 2.60.0011 25ACM T PROGR LANG SYS0164-09251500 1.444 1.7820.05139>10.00.00236 26ACM T SOFTW ENG METH1049-331X729 3.958 4.2930.261237.80.00165 27ACOUST PHYS+1063-77105310.6220.5360.125112 5.60.0011 28ACS CHEM BIOL1554-8929867 5.149 5.149 1.35177 1.80.00713 29ACS NANO1936-0851703 5.472 5.472 1.3892960.90.00214 30ACSMS HEALTH FIT J1091-5397630.3530.3660.042240.00026 31ACTA ACUST UNITED AC1610-192814730.5380.6790.08100>10.00.00423 32ACTA AGR SCAND A-AN0906-********.4890.7160.088349.30.00055 33ACTA AGR SCAND B-S P0906-********.4070.5120.1765180.0006734ACTA ALIMENT HUNG0139-30063190.4410.5340438.40.00046 35ACTA ANAESTH SCAND0001-51724842 1.953 1.9010.5031997.10.01055 36ACTA APPL MATH0167-80197880.430.570.218878.20.00391 37ACTA ARITH0065-103611840.4670.4840.11444>10.00.00694 38ACTA ASTRONAUT0094-576512120.3740.4240.0132318.60.00314 39ACTA ASTRONOM0001-5237860 1.778 1.8850.7309.30.00264 40ACTA BIOCH BIOPH SIN1672-9145825 1.0860.9370.163123 3.80.00343 41ACTA BIOCHIM POL0001-527X1655 1.448 1.890.23793 5.40.0065 42ACTA BIOL CRACOV BOT0001-52961420.3510.49201350.00051 43ACTA BIOL HUNG0236-53833710.6190.6920.067758.20.00089 44ACTA BIOMATER1742-70611176 3.727 4.2550.491216 2.30.00703 45ACTA BIOQUIM CLIN L0325-2957390.0440.1110.077130.00008 46ACTA BIOTHEOR0001-53424230.7350.8620.05618>10.00.00099 47ACTA BOT GALLICA1253-80781250.1450.2240.0249>10.00.0003 48ACTA CARDIOL0001-53856210.5810.6260.096104 5.80.0018 49ACTA CHIM SINICA0567-735123390.6820.6740.067461 4.50.00462 50ACTA CHIM SLOV1318-02075860.9090.9320.109101 3.90.00224 51ACTA CHIR BELG0001-54587290.4740.5540.06167 5.10.00228 52ACTA CHIROPTEROL1508-11092900.825 1.0890.02638 4.80.0014 53ACTA CHROMATOGR1233-23561620.6210.8260.11154 3.50.00072 54ACTA CLIN BELG0001-5512528 1.282 1.0090.0545640.00201 55ACTA CRYSTALLOGR A0108-767311622 2.051 2.09849.55672>10.00.00741 56ACTA CRYSTALLOGR B0108-768110332 2.341 2.3310.41986>10.00.00928 57ACTA CRYSTALLOGR C0108-270161190.5610.5730.354328>10.00.00883 58ACTA CRYSTALLOGR D0907-44499365 2.943 1.8270.5811489.70.03266 59ACTA CRYSTALLOGR E1600-536871130.3670.3670.2933533 2.40.01858 60ACTA CRYSTALLOGR F1744-30915860.6060.195293 2.30.00553 61ACTA CYTOL0001-554727130.8350.9030.093118>10.00.00294 62ACTA DERM-VENEREOL0001-55553545 2.456 2.2540.28474>10.00.00456 63ACTA DIABETOL0940-54298390.926 1.370.12133 6.80.00203 64ACTA ENDOSC0240-642X620.0740.028720.00004 65ACTA ETHOL0873-********.6670.07114 6.40.00055 66ACTA GASTRO-ENT BELG0001-56444250.8320.7780.11435 6.10.00088 67ACTA GEOL POL0001-57094150.5810.16742>10.00.00084 68ACTA GEOL SIN-ENGL1000-95151312 1.431 1.5890.153118 4.70.00375 69ACTA GEOPHYS1895-65721570.3080.22263 6.10.0005470ACTA HAEMATOL-BASEL0001-57921582 1.191 1.1980.061829.20.00333 71ACTA HISTOCHEM0065-1281719 1.101 1.1540.29857 6.90.00157 72ACTA HISTOCHEM CYTOC0044-59912210.8570.4820.048218.50.00052 73ACTA HYDROCH HYDROB0323-43204860.907 1.1610 6.50.00154 74ACTA INFORM0001-59037340.789 1.0460.28621>10.00.00128 75ACTA MATER1359-645423367 3.729 4.4110.542612 5.70.11179 76ACTA MATH HUNG0236-52949610.3170.4690.077104>10.00.00428 77ACTA MATH SCI0252-96023010.2220.352099 6.60.00138 78ACTA MATH SIN1439-85169610.5430.6410.05179 5.70.00624 79ACTA MATH-DJURSHOLM0001-59622425 2.143 2.3710.27311>10.00.0046 80ACTA MECH0001-59701956 1.297 1.240.1891279.90.00611 81ACTA MECH SINICA0567-77186060.9390.9090.12274 5.20.0025 82ACTA MECH SOLIDA SIN0894-91662630.5520.6180.04370 5.70.00084 83ACTA MED OKAYAMA0386-300X4780.9690.9680.12755 6.80.00121 84ACTA METALL SIN0412-********.4740.4250.075268 5.40.00265 85ACTA NEUROBIOL EXP0065-1400622 1.091 1.3450.21252 6.70.00164 86ACTA NEUROCHIR0001-62685219 1.634 1.7260.148176>10.00.00891 87ACTA NEUROL BELG0300-90093910.770.70303490.00073 88ACTA NEUROL SCAND0001-63145485 2.317 2.390.4521359.90.01118 89ACTA NEUROPATHOL0001-63227726 5.31 3.787 1.6721198.90.01833 90ACTA NEUROPSYCHIATR0924-2708237 1.38 1.0530.2962 2.80.00072 91ACTA OBSTET GYN SCAN0001-63495280 1.356 1.6990.3371967.70.0127 92ACTA OCEANOL SIN0253-505X5120.4410.6240.03488 5.70.00109 93ACTA ODONTOL SCAND0001-63572205 1.095 1.540.12158>10.00.00284 94ACTA OECOL1146-609X1559 1.456 1.6950.1698970.00452 95ACTA ONCOL0284-186X3416 2.739 2.5610.8471767.30.0078 96ACTA OPHTHALMOL1755-375X3875 2.138 1.9430.4631479.90.00749 97ACTA ORNITHOL0001-64542760.882 1.0670.56730 5.80.00056 98ACTA ORTHOP1745-36745870 1.762 1.9680.274124>10.00.00913 99ACTA OTO-LARYNGOL0001-648951520.868 1.0350.072223>10.00.00959 100ACTA PAEDIATR0803-52538608 1.517 1.740.2223209.50.01904 101ACTA PALAEONTOL POL0567-7920777 1.128 1.2390.20454 6.60.00291 102ACTA PARASITOL1230-28214720.7480.8350.0885770.00158 103ACTA PHARMACOL SIN1671-40833498 1.676 1.7310.20918750.01085 104ACTA PHYS POL A0587-42468290.3210.3240.069525 6.80.00216 105ACTA PHYS POL B0587-425417500.7670.5910.19627650.00928106ACTA PHYS SIN-CH ED1000-32906421 1.165 1.0230.1361262 3.30.00618 107ACTA PHYS SLOVACA0323-04652620.7240.56706 5.10.00144 108ACTA PHYS-CHIM SIN1000-681812300.6730.5540.129410 3.70.00281 109ACTA PHYSIOL1748-1708568 2.455 2.470.579114 2.10.00328 110ACTA PHYSIOL HUNG0231-424X3010.4910.06929>10.00.00034 111ACTA PHYSIOL PLANT0137-58815480.8070.7640.143105 6.90.00116 112ACTA PHYTOTAXON SIN0529-15264170.3240.3330>10.00.00068 113ACTA POLYM SIN1000-33048230.5650.5510.045200 4.60.00138 114ACTA PROTOZOOL0065-1583493 1.0130.9140167.60.00128 115ACTA PSYCHIAT SCAND0001-690X9264 3.525 3.8010.509114>10.00.01668 116ACTA RADIOL0284-18512991 1.091 1.2980.163172100.00622 117ACTA SOC BOT POL0001-69774330.4180.4130.08945>10.00.0004 118ACTA THERIOL0001-70511065 1.118 1.020.22631>10.00.00156 119ACTA TROP0001-706X3373 1.707 2.3750.308169 6.10.01033 120ACTA VET BRNO0001-72134430.3950.5660.03488 5.70.00089 121ACTA VET HUNG0236-62904170.6240.6640.304567.10.00081 122ACTA VET SCAND0044-605X9740.8990.8220.06248>10.00.00129 123ACTA VET-BEOGRAD0567-83151080.1670.202058 6.30.00021 124ACTA VIROL0001-723X6830.810.8880.08834>10.00.00075 125ACTA ZOOL ACAD SCI H1217-88372020.5220.3590.08324>10.00.0003 126ACTA ZOOL-STOCKHOLM0001-7272699 1.333 1.2710.2532>10.00.00138 127ACTAS ESP PSIQUIATRI1139-92872540.4460.5430.0650 4.80.00069 128ACTUAL CHIMIQUE0151-9093950.1520.14301000.00039 129ACUPUNCTURE ELECTRO0360-12932430.6920.7820.05319>10.00.0002 130ADANSONIA1280-85712130.4440.26715>10.00.00043 131ADAPT BEHAV1059-7123434 1.152 1.840.19217.50.00093 132ADAPT PHYS ACT Q0736-********.837 1.0090189.30.00057 133ADDICT BEHAV0306-46035389 1.846 2.2720.28618570.01737 134ADDICT BIOL1355-6215842 4.953 3.0920.6346 3.70.00377 135ADDICTION0965-21409861 4.244 5.185 1.378201 6.20.03281 136ADSORPT SCI TECHNOL0263-61745540.4240.687032 6.90.00122 137ADSORPTION0929-5607791 1.237 1.2690.14682 4.80.00298 138ADV AGRON0065-21132025 3.114 3.7050.07128>10.00.00349 139ADV ANAT EMBRYOL CEL0301-5556351 1.778306>10.00.00072 140ADV ANAT PATHOL1072-4109846 3.69 3.260.53330 4.10.00345 141ADV APPL CERAM1743-67531200.7080.8080.03754 2.80.00104142ADV APPL CLIFFORD AL0188-7009850.3960.115610.00022 143ADV APPL MATH0196-88588630.6960.8690.238637.90.00595 144ADV APPL MECH0065-21569285 4.18203>10.00.00052 145ADV APPL MICROBIOL0065-2164705 1.658 2.2050.2425>10.00.00184 146ADV APPL PROBAB0001-867815440.807 1.0350.09354>10.00.00648 147ADV ATMOS SCI0256-15308320.6790.9210.15696 5.70.00321 148ADV ATOM MOL OPT PHY1049-250X828 2.762 3.109 1.231139.20.00236 149ADV BIOCHEM ENG BIOT0724-******** 2.569 2.7510.67731 5.70.00441 150ADV CANCER RES0065-230X1885 4.721 5.8180.9572390.00427 151ADV CARBOHYD CHEM BI0065-23187473 3.2>10.00.00035 152ADV CATAL0360-05641441 4.812 6.80>10.00.00109 153ADV CEM RES0951-********.4760.6830.19219.60.00118 154ADV CHROMATOGR0065-2415224 2.6 2.036>10.00.00042 155ADV CHRONIC KIDNEY D1548-5595291 1.673 1.5060.44445 2.60.00171 156ADV CLIN CHEM0065-2423327 3.094 3.0310.516 4.30.00106 157ADV COLLOID INTERFAC0001-86864491 5.333 5.650.958487.50.01265 158ADV COMPLEX SYST0219-52592500.1970.7080.12755 6.10.00092 159ADV COMPOS LETT0963-6935810.270.223080.00022 160ADV COMPOS MATER0924-30461310.4040.488026 6.70.00041 161ADV COMPUT0065-24581670.2670.6520169.30.0004 162ADV COMPUT MATH1019-7168948 1.148 1.2560.486379.30.00361 163ADV DIFFER EQU-NY1687-18391050.4940.21138 3.10.00065 164ADV DRUG DELIVER REV0169-409X124558.28710.625 2.302126 6.40.03288 165ADV ECOL RES0065-25041402 1.2 3.9290.23821>10.00.00215 166ADV ENG INFORM1474-0346354 1.848 2.4310.31741 3.50.00152 167ADV ENG MATER1438-16562394 1.506 1.9810.253174 4.60.01291 168ADV ENG SOFTW0965-9978897 1.188 1.0480.18990 6.40.00268 169ADV FUNCT MATER1616-301X12257 6.8088.2030.758422 3.30.08039 170ADV GEOM1615-715X1220.3240.420.22236 4.50.00199 171ADV GEOPHYS0065-2687432 2.1 2.50.05319>10.00.00044 172ADV HEALTH SCI EDUC1382-4996327 1.254 1.5450.250 4.80.00137 173ADV HETEROCYCL CHEM0065-2725820 1.35 1.68908>10.00.00047 174ADV IMMUNOL0065-277622458.6257.0780.227229.70.00946 175ADV INORG CHEM0898-******** 4.214 4.54306>10.00.00211 176ADV INSECT PHYSIOL0065-28063795 5.545 4.52>10.00.00067 177ADV MAR BIOL0065-2881932 4.909 5.3160.5717>10.00.00183178ADV MATER0935-9648490088.19110.2310.957772 5.30.21333 179ADV MATER PROCESS0882-79583220.1290.2510.037828.20.00087 180ADV MATH0001-87083620 1.28 1.4290.3220>10.00.03207 181ADV MATH COMMUN1930-5346320.970.970260.00055 182ADV MICROB PHYSIOL0065-29119048.258.708 1.754>10.00.00223 183ADV NONLINEAR STUD1536-13651440.5620.8380.07938 4.30.00196 184ADV NURS SCI0161-9268929 1.211 1.4510.17229>10.00.00103 185ADV ORGANOMET CHEM0065-3055889 3.571 5.364 1.53813>10.00.00151 186ADV PARASIT0065-308X1153 5.514 5.708 1.548.90.00312 187ADV PHYS0001-8732398015.82613.3530.58>10.00.01047 188ADV PHYS ORG CHEM0065-3160487 1.833 2.6360.3336>10.00.00052 189ADV PHYSIOL EDUC1043-4046438 1.483 1.7230.22744 4.50.00134 190ADV POLYM SCI0065-31953725 6.8027.0890.3855290.01183 191ADV POLYM TECH0730-********.979 1.061068.90.00096 192ADV POWDER TECHNOL0921-88312370.7160.6560.05934 4.90.00112 193ADV PROTEIN CHEM0065-32332693 3.875 5.58604>10.00.00848 194ADV QUANTUM CHEM0065-327672930.990.30559>10.00.00154 195ADV ROBOTICS0169-18644880.7370.9090.11181 5.20.00145 196ADV SPACE RES0273-117759790.860.26549 5.60.0261 197ADV STRUCT ENG1369-43321510.5130.04248 3.80.00134 198ADV STUD BEHAV0065-3454881 2.5 4.1840.2229>10.00.00204 199ADV SYNTH CATAL1615-41508217 5.619 5.458 1.008368 3.20.04806 200ADV THEOR MATH PHYS1095-07612073 2.0750.53132>10.00.00594 201ADV THER0741-238X5910.9730.9970.074122 3.50.00218 202ADV VIRUS RES0065-35271279 4.886 5.4950117.60.00494 203ADV WATER RESOUR0309-17082918 2.235 2.440.423137 5.80.01317 204AEROBIOLOGIA0393-******* 1.0860.125247.40.00118 205AERONAUT J0001-92403950.2920.3680.04566>10.00.00107 206AEROSOL SCI TECH0278-68263636 2.686 2.9270.303897.30.01263 207AEROSP SCI TECHNOL1270-96384960.740.9180.08868 4.70.00324 208AEROSPACE AM0740-722X720.0480.0530.013790.00037 209AESTHET PLAST SURG0364-216X13840.782 1.0780.1551428.10.00296 210AEU-INT J ELECTRON C1434-84113480.3710.4370.01105 6.20.00101 211AFINIDAD0001-97041880.2440.2450.07540 6.50.00043 212AFR ENTOMOL1021-35892290.3080.4880.07938 6.50.00063 213AFR J BIOTECHNOL1684-531511550.5470.06870130.00366214AFR J ECOL0141-670710060.6210.930.0711580.00251 215AFR J HERPETOL0441-6651690.6040.00031 216AFR J MAR SCI1814-232X434 1.312 1.4160.75549 2.90.00215 217AFR J MICROBIOL RES1996-080890.4090.4090450.00003 218AFR ZOOL1562-70201470.4370.5270.13829 5.20.00064 219AGE0161-9152661 5.105 5.03 1.82417 4.70.00246 220AGE AGEING0002-07294405 3.052 3.1180.5981027.80.01061 221AGEING RES REV1568-16371064 6.209 6.288 2.0425 4.20.00549 222AGGRESSIVE BEHAV0096-140X1454 2.056 2.1290.245538.80.00376 223AGING CELL1474-971820837.7917.585 1.05985 2.70.01673 224AGING CLIN EXP RES1594-06671426 1.397 1.7840.16585 6.50.0039 225AGING MALE1368-5538351 2.6220.08324 4.30.00114 226AGING MENT HEALTH1360-78631009 1.291 1.890.14192 4.90.00354 227AGR ECON-BLACKWELL0169-51507770.4840.910.26376 6.90.0025 228AGR ECOSYST ENVIRON0167-88096468 2.884 2.980.425186 6.20.02259 229AGR FOOD SCI1459-60672690.6970.7360.09432 6.70.00055 230AGR FOREST ENTOMOL1461-9555535 1.377 1.6960.24549 5.30.0023 231AGR FOREST METEOROL0168-19237232 3.668 4.4860.81607.40.02204 232AGR HIST0002-14821070.0970.205015>10.00.00016 233AGR HUM VALUES0889-048X520 1.186 1.3190.064477.20.00172 234AGR SYST0308-521X1876 1.708 1.8930.42264 6.50.00639 235AGR WATER MANAGE0378-******** 1.646 1.8290.196138 5.40.00887 236AGRO FOOD IND HI TEC1722-69961530.1890.1730.034118 4.60.00044 237AGROCHIMICA0002-18572180.1790.3510.05934>10.00.00024 238AGROCIENCIA-MEXICO1405-31952040.2320.3420.05690 4.70.00045 239AGROFOREST SYST0167-436614420.845 1.1640.162689.20.00262 240AGRON J0002-19628449 1.532 1.9950.237245>10.00.01416 241AGRON SUSTAIN DEV1774-0746228 1.649 1.4960.32259 2.40.00111 242AI COMMUN0921-71263100.6080.680.03826>10.00.00059 243AI EDAM0890-********.477 1.0490247.20.00048 244AI MAG0738-********.691 1.4190.04224>10.00.00121 245AIAA J0001-14529941 1.025 1.260.14301>10.00.01955 246AICHE J0001-154114509 1.883 2.3340.282277>10.00.02687 247AIDS0269-937020159 5.46 5.561 1.309353 5.70.07848 248AIDS PATIENT CARE ST1087-29141489 2.392 2.4860.30997 4.10.00622 249AIDS RES HUM RETROV0889-22294244 2.024 2.080.38319670.01346250AIDS REV1139-6121489 3.2680.33321 4.30.00362 251AIRCR ENG AEROSP TEC1748-88421040.1830.1410.004281 4.40.00038 252AKTUEL NEUROL0302-43501500.2950.2170.03458 4.10.00024 253AKTUEL RHEUMATOL0341-051X1110.0840.2330.1353760.00011 254AKTUEL UROL0001-7868960.1680.2520.043470.00023 255ALCATEL TELECOMMUN R1267-7167280.0150.09800.0001 256ALCHERINGA0311-********.5120.5040.03826>10.00.00051 257ALCOHOL0741-83292239 2.363 2.3590.357708.40.00481 258ALCOHOL ALCOHOLISM0735-******** 2.137 2.3510.331067.30.00706 259ALCOHOL CLIN EXP RES0145-600811358 3.166 3.3260.5672317.60.02672 260ALDRICHIM ACTA0002-510084916.73312.91226 5.40.0037 261ALGEBR COLLOQ1005-38671770.240.2650.15465 6.20.00159 262ALGEBR GEOM TOPOL1472-27393540.550.09111 4.40.00695 263ALGEBR REPRESENT TH1386-923X1780.7760.6390.19431 4.20.00294 264ALGEBR UNIV0002-52404980.3130.4610.06958>10.00.00214 265ALGORITHM MOL BIOL1748-718881 2.0810.231130.00077 266ALGORITHMICA0178-461715300.825 1.2220.2374100.00559 267ALIMENT PHARM THER0269-28133089 1.215 1.2050.66268 4.90.01252 268ALLELOPATHY J0971-********.5250.6150.0439240.00044 269ALLERGOLOGIE0344-50621910.1750.2010.015669.90.00012 270ALLERGY0105-45389947 6.204 5.553 1.362188 5.10.02893 271ALLERGY ASTHMA PROC1088-5412941 1.487 1.2640.28100 4.10.00299 272ALLG FORST JAGDZTG0002-58521630.4440.4350.06929>10.00.0003 273ALTERN MED REV1089-5159846 2.8080.18816 6.80.00205 274ALTERN THER HEALTH M1078-6791752 2.25 2.112 5.70.00239 275ALTEX-ALTERN TIEREXP0946-7785286 1.309 1.1710.92928 3.40.00043 276ALZ DIS ASSOC DIS0893-******** 3.22 3.2040.385060.0057 277AM BEE J0002-76264110.1550.1180.008119>10.00.00074 278AM BIOL TEACH0002-76852560.3080.3460.033608.90.00044 279AM CERAM SOC BULL0002-781218080.3240.3820.05555>10.00.00144 280AM FAM PHYSICIAN0002-838X3751 1.94 2.1070.345139 6.20.00936 281AM FERN J0002-84442680.3710.4040.06216>10.00.00019 282AM HEART J0002-870318847 4.285 4.1860.9093427.20.06049 283AM J AGR ECON0002-909234050.967 1.5340.111108>10.00.00739 284AM J BIOETHICS1526-51611062 4.378 4.362 6.940 2.60.00454 285AM J BOT0002-912211858 2.642 3.1510.497151>10.00.02562286AM J CARDIOL0002-914935642 3.905 3.5520.5986967.70.10083 287AM J CHINESE MED0192-415X1089 1.058 1.0760.08297 6.30.0021 288AM J CLIN DERMATOL1175-05611137 1.554 2.570.24657 5.50.00395 289AM J CLIN NUTR0002-916538998 6.747.679 1.08345880.09491 290AM J CLIN ONCOL-CANC0277-37322859 1.792 1.8520.1551037.20.00663 291AM J CLIN PATHOL0002-91739429 2.715 2.9860.4282159.50.01945 292AM J CRIT CARE1062-32641218 2.043 2.0650.39251 6.60.00301 293AM J DENT0894-82751822 1.13 1.5290.108747.60.00372 294AM J DERMATOPATH0193-10912541 1.477 1.7660.2111239.10.00406 295AM J EMERG MED0735-******** 1.188 1.5610.4131438.10.00713 296AM J ENOL VITICULT0002-92543623 1.689 2.010.1958>10.00.00333 297AM J EPIDEMIOL0002-926228967 5.454 6.404 1.2582959.50.07706 298AM J FOREN MED PATH0195-791010330.5230.8950.023878.50.00243 299AM J GASTROENTEROL0002-927026249 6.444 6.432 1.106339 6.80.06526 300AM J GERIAT PSYCHIAT1064-74813152 4.022 4.2120.741112 3.90.01367 301AM J GERIATR CARDIOL1076-7460294 1.080.78614 4.60.00108 302AM J HEALTH-SYST PH1079-20822935 1.763 1.7440.508199 4.70.00942 303AM J HEMATOL0361-86094740 2.126 2.1180.7361747.10.01244 304AM J HUM BIOL1042-05331523 1.976 2.1340.34493 5.60.00553 305AM J HUM GENET0002-92973298010.15311.306 3.0392047.10.135 306AM J HYPERTENS0895-70617748 3.122 3.4760.739203 6.30.02159 307AM J IND MED0271-35864517 1.489 1.8630.241009.60.00747 308AM J INFECT CONTROL0196-65533349 2.678 3.2930.291127 5.90.01249 309AM J KIDNEY DIS0272-638617555 4.822 4.908 1.452248 6.70.04098 310AM J MANAG CARE1088-02242166 2.22 2.5530.83384 4.40.01137 311AM J MATH0002-93273354 1.316 1.3190.19252>10.00.00988 312AM J MED0002-934323727 5.105 5.23 1.045201>10.00.04895 313AM J MED GENET A1552-48254825 2.555 2.2270.378376 3.40.03595 314AM J MED GENET B1552-48413288 3.932 4.2670.577227 3.40.02268 315AM J MED GENET C1552-4868751 3.209 4.4610.41429 3.70.00591 316AM J MED QUAL1062-8606431 1.365 1.4030.22245 4.30.00213 317AM J MED SCI0002-96293547 1.36 1.5150.129194>10.00.00656 318AM J NEPHROL0250-80952394 3.164 3.1140.742120 5.80.00688 319AM J NEURORADIOL0195-610814463 2.745 3.010.5283717.10.0384 320AM J NURS0002-936X975 1.0460.960.13894 6.60.00231 321AM J OBSTET GYNECOL0002-937831602 3.453 3.5720.5815669.50.06363322AM J OPHTHALMOL0002-939417315 3.102 3.0220.74527880.04634 323AM J ORTHOD DENTOFAC0889-54068040 1.442 2.0160.121239>10.00.01008 324AM J ORTHOPSYCHIAT0002-94322866 1.711 2.4250.1753>10.00.00557 325AM J OTOLARYNG0196-070913900.845 1.0750.06848.70.00336 326AM J PATHOL0002-944034497 5.697 6.20.8523247.80.09795 327AM J PERINAT0735-******** 1.158 1.1250.1851089.40.00296 328AM J PHARM EDUC0002-94597050.9360.8820.188117 4.90.00049 329AM J PHYS0002-950547010.8310.9770.262164>10.00.00648 330AM J PHYS ANTHROPOL0002-94837241 2.353 2.690.456147>10.00.01257 331AM J PHYS MED REHAB0894-91152924 1.695 1.8680.202124 6.80.0074 332AM J PHYSIOL-CELL PH0363-614316421 4.23 4.1710.635323 6.70.05999 333AM J PHYSIOL-ENDOC M0193-184916765 3.855 4.1290.75130170.05338 334AM J PHYSIOL-GASTR L0193-185713313 3.587 3.6450.8122987.10.03663 335AM J PHYSIOL-HEART C0363-613528177 3.643 3.7360.594608 6.50.094 336AM J PHYSIOL-LUNG C1040-060511814 3.924 4.0610.75323560.0433 337AM J PHYSIOL-REG I0363-611917691 3.272 3.5560.6834587.40.05174 338AM J PHYSIOL-RENAL0363-612713879 3.89 4.0880.622368 6.30.04633 339AM J POTATO RES1099-209X4000.6040.890.15645 5.80.00108 340AM J PREV MED0749-37978625 3.766 4.863 2.883230 5.30.03486 341AM J PRIMATOL0275-25652625 1.681 2.1290.3211409.30.00617 342AM J PSYCHIAT0002-953X4153710.54510.806 3.1131248.10.10932 343AM J PUBLIC HEALTH0090-003622465 4.241 4.9840.7842648.50.06395 344AM J REPROD IMMUNOL1046-74082646 2.172 2.2230.4231117.40.00514 345AM J RESP CELL MOL1044-15499381 4.477 4.2820.921177 6.90.03084 346AM J RESP CRIT CARE1073-449X435959.7929.263 2.1593097.30.11875 347AM J RHINOL ALLERGY1050-65861426 1.553 1.6910.197122 4.30.00505 348AM J ROENTGENOL0361-803X24743 2.94 2.910.4965818.80.05119 349AM J SCI0002-95994607 2.27 3.4610.24337>10.00.00682 350AM J SPORT MED0363-546511840 3.646 3.9520.5222558.80.02806 351AM J SURG0002-961015354 2.605 2.8480.367311>10.00.02695 352AM J SURG PATHOL0147-518514886 4.02 4.8330.6232288.30.02963 353AM J TRANSPLANT1600-613510903 6.559 6.281 1.213310 3.20.06443 354AM J TROP MED HYG0002-963714051 2.45 2.7150.45633890.0342 355AM J VET RES0002-96459210 1.28 1.4320.243218>10.00.00935 356AM LAB0044-77493230.1640.2030.0281077.90.00076 357AM MALACOL BULL0740-27833500.3750.6920.23343>10.00.00056358AM MATH MON0002-989020110.3610.3380.0989>10.00.0033 359AM MIDL NAT0003-003132820.7550.9920.09386>10.00.00319 360AM MINERAL0003-004X11340 1.962 2.2860.364220>10.00.02554 361AM MUS NOVIT0003-00821757 1.265 1.3080.22236>10.00.00255 362AM NAT0003-014721622 4.67 5.5080.784190>10.00.04817 363AM SCI0003-09961698 1.186 1.1090.33342>10.00.00273 364AM STAT0003-13052398 1.233 1.3180.28945>10.00.00377 365AM SURGEON0003-13485928 1.297 1.6610.1192188.50.01166 366AMAZONIANA0065-67551750.1430.3870>10.00.00018 367AMBIO0044-74473115 2.092 2.230.802818.10.00882 368AMBUL PEDIATR1530-1567886 1.846 2.0450.39653 4.60.00473 369AMEGHINIANA0002-70148900.7410.9030.07341>10.00.00169 370AMINO ACIDS0939-44512672 4.132 3.5590.846169 3.30.0096 371AMPHIBIA-REPTILIA0173-53737580.7840.890.106667.70.00186 372AMYLOID1350-6129698 1.714 1.9090.10329 6.20.00207 373AMYOTROPH LATERAL SC1748-2968759 1.815 1.8230.44949 5.30.00243 374AN ACAD BRAS CIENC0001-37658560.881 1.090.1608.40.00225 375ANAEROBE1075-9964653 1.561 1.3830.0854770.00197 376ANAESTH INTENS CARE0310-057X16590.8480.9690.2181198.30.00332 377ANAESTHESIA0003-24095868 2.178 2.350.7921788.70.01048 378ANAESTHESIST0003-241711460.8760.790.29124 6.40.00153 379ANAL BIOANAL CHEM1618-264210385 3.328 3.1070.595654 3.30.05731 380ANAL BIOCHEM0003-269736555 3.088 3.1450.723433>10.00.04836 381ANAL CHEM0003-270077792 5.712 5.9180.83112217.30.19839 382ANAL CHIM ACTA0003-267030968 3.146 3.170.504674 6.30.08162 383ANAL LETT0003-27192879 1.281 1.2190.129240 6.30.00687 384ANAL SCI0910-******** 1.735 1.6020.296277 5.40.01373 385ANALOG INTEGR CIRC S0925-10306780.5910.5160.0219780.0017 386ANALYST0003-265411181 3.761 3.4720.6772268.50.0227 387ANASTH INTENSIV NOTF0939-26613620.1940.2940.011937.70.00053 388ANAT EMBRYOL0340-20612588 1.39 1.5740>10.00.00383 389ANAT HISTOL EMBRYOL0340-20965590.5730.6940.04883 6.50.00133 390ANAT REC1932-84866454 1.569 2.0220.285158>10.00.01031 391ANAT SCI INT1447-69592150.5940.1250 4.40.00114 392ANDROLOGIA0303-4569991 1.3 1.4750.232698.50.00172 393ANESTH ANALG0003-299918093 2.59 2.4390.89552670.04062394ANESTHESIOLOGY0003-302220294 5.124 4.506 1.2612388.20.04367 395ANGEW CHEM INT EDIT1433-785113953410.87911.025 2.6571797 4.90.51352 396ANGIOLOGY0003-31972056 1.122 1.1230.1081399.40.00294 397ANGLE ORTHOD0003-32193353 1.166 1.6710.121679.50.00854 398ANIM BEHAV0003-347218476 2.828 3.350.55402>10.00.03659 399ANIM BIOL1570-75551820.8790.9590.372740.00109 400ANIM BIOTECHNOL1049-53982670.759 1.0580.03727 6.50.0007 401ANIM CELLS SYST1976-835410410 402ANIM COGN1435-9448879 2.699 3.0570.43873 4.70.00407 403ANIM CONSERV1367-94301194 2.587 2.8340.69656 4.90.00586 404ANIM FEED SCI TECH0377-******** 1.882 2.2430.312108.40.00924 405ANIM GENET0268-91462456 2.459 2.6020.27411770.00633 406ANIM REPROD SCI0378-******** 1.89 2.3950.376263 6.30.00903 407ANIM RES1627-35833830.917 1.5310 4.90.00179 408ANIM SCI1357-72982066 1.559 1.642080.00416 409ANIM SCI J1344-39413570.7130.19896 3.80.00127 410ANIM SCI PAP REP0860-40371450.214033 5.30.00033 411ANIM WELFARE0962-72868480.669 1.1790.23139 6.60.0023 412ANIMAL1751-73112340.994 1.0060.292219 1.30.001 413ANN ACAD MED SINGAP0304-46021587 1.00410.418146 6.40.00407 414ANN ACAD SCI FENN-M1239-629X5500.7140.9480.08137>10.00.00325 415ANN AGR ENV MED1232-1966634 1.443 1.5580.05951 4.90.00184 416ANN ALLERG ASTHMA IM1081-12065410 2.353 2.3670.657178 6.70.01352 417ANN ANAT0940-96026420.9320.8440.13253 6.30.00166 418ANN APPL BIOL0003-47463071 1.868 1.9670.29179>10.00.00493 419ANN APPL PROBAB1050-51641593 1.285 1.7380.267867.40.01459 420ANN APPL STAT1932-615797 2.448 2.4830.403620.00104 421ANN BIOL CLIN-PARIS0003-38984860.2860.3810.049828.70.00065 422ANN BIOMED ENG0090-69644487 2.605 2.9990.299184 5.40.01795 423ANN BOT FENN0003-38476370.3610.6380.03164>10.00.00142 424ANN BOT-LONDON0305-73649381 2.755 3.4040.6322207.60.02596 425ANN CARNEGIE MUS0097-44633430.7610.11526>10.00.0005 426ANN CHIM-ROME0003-45929280.5890.6320>10.00.00191 427ANN CHIM-SCI MAT0151-91074460.5510.3720.118348.30.001 428ANN CHIR0003-39447270.5210.50908.30.00093 429ANN CLIN BIOCHEM0004-56322040 1.788 1.7890.27810880.00399430ANN CLIN LAB SCI0091-7370954 1.357 1.2120.085597.90.00215 431ANN COMB0218-00062270.460.09122 6.30.00217 432ANN DERMATOL VENER0151-963814470.4820.610.0752527.80.00203 433ANN EMERG MED0196-06448227 3.755 3.5970.9941549.20.01826 434ANN ENDOCRINOL-PARIS0003-42663680.4460.4140.0916670.00065 435ANN ENTOMOL SOC AM0013-87464290 1.241 1.5020.252135>10.00.00739 436ANN EPIDEMIOL1047-27973928 2.62130.496117 6.70.01534 437ANN FAM MED1544-17091555 3.541 2.33962 3.60.01155 438ANN FOREST SCI1286-45601312 1.554 1.5920.14192 5.30.00452 439ANN FR ANESTH0750-765810490.7930.6610.31313460.00137 440ANN GEOPHYS-GERMANY0992-******** 1.66 1.7580.299328 5.30.02134 441ANN GEOPHYS-ITALY1593-52134390.4180.844 4.40.00428 442ANN GLOB ANAL GEOM0232-704X3450.6250.750.102497.40.00283 443ANN HEMATOL0939-55552582 2.454 2.2170.5298 5.30.00874 444ANN HENRI POINCARE1424-0637439 1.2340.9360.1024950.00512 445ANN HUM BIOL0301-44601387 1.009 1.3490.14854>10.00.00263 446ANN HUM GENET0003-48002340 2.195 2.5940.632877.70.00855 447ANN I FOURIER0373-095614570.8020.9030.14370>10.00.01007 448ANN I H POINCARE-AN0294-144910780.878 1.3710.19656>10.00.00616 449ANN I H POINCARE-PR0246-02034780.6440.8310.0755380.00474 450ANN I STAT MATH0020-31579590.5650.6390.04842>10.00.00319 451ANN INTERN MED0003-48194478517.45716.117 4.5741628.80.12606 452ANN LIMNOL-INT J LIM0003-40882470.7680.8030.0825 6.80.00066 453ANN MAT PUR APPL0373-311410680.8180.22935>10.00.00317 454ANN MATH0003-486X7467 3.447 3.575 1.02442>10.00.02644 455ANN MATH ARTIF INTEL1012-24435830.7220.803057.80.0018 456ANN MED0785-38903222 5.435 4.590.7564 6.60.01166 457ANN MED VET0003-41181110.1290.155016>10.00.00013 458ANN MICROBIOL1590-42612720.4660.5290.085117 4.50.00082 459ANN MO BOT GARD0026-64932212 1.246 1.540.31232>10.00.00196 460ANN NEUROL0364-5134287109.9359.081 2.1661698.50.08 461ANN NONINVAS ELECTRO1082-720X485 1.12 1.3740.1325340.00232 462ANN NUCL ENERGY0306-454910080.8310.8140.108269 5.80.00417 463ANN NUCL MED0914-******* 1.099 1.0880.109129 4.90.00301 464ANN NUTR METAB0250-68071271 1.236 1.8740.11181 6.30.00317 465ANN NY ACAD SCI0077-892337539 2.303 2.3790.1959757.50.11225466ANN OCCUP HYG0003-48781868 1.787 2.0630.347727.70.00412 467ANN ONCOL0923-753415689 4.935 5.303 1.377419 4.60.05407 468ANN OPER RES0254-533022820.619 1.1630.0871159.50.00726 469ANN OPHTHALMOL1530-40866110.0940.095038>10.00.00014 470ANN OTO RHINOL LARYN0003-48945566 1.339 1.3650.175154>10.00.00835 471ANN PALEONTOL0753-********.20.06715>10.00.00037 472ANN PATHOL0242-64984550.4740.5710.1910070.00057 473ANN PHARMACOTHER1060-02805576 2.305 2.1530.466221 5.20.01669 474ANN PHYS-BERLIN0003-38042255 1.161 1.250.43848>10.00.00289 475ANN PHYS-NEW YORK0003-49169072 3.171 3.040.93142>10.00.02018 476ANN PHYS-PARIS0003-41692230.180.37311>10.00.00037 477ANN PLAS SURG0148-70435051 1.14 1.4090.162449.10.01207 478ANN PROBAB0091-17983165 1.278 1.5870.35673>10.00.01727 479ANN PURE APPL LOGIC0168-00727760.5510.6580.13699.50.00409 480ANN REV BIOPHYS1936-122X61 2.435230 481ANN RHEUM DIS0003-4967178077.188 6.792 1.96430250.05717 482ANN ROY COLL SURG0035-884318230.944 1.0390.124121>10.00.00363 483ANN SAUDI MED0256-49475440.60.5810.19189 6.80.00107 484ANN SCI0003-37901820.3510.2920.05618>10.00.00087 485ANN SCI ECOLE NORM S0012-95931446 1.196 1.5990.17617>10.00.00788 486ANN SCUOLA NORM-SCI0391-173X10180.5190.08723>10.00.00269 487ANN SOC ENTOMOL FR0037-92718360.9340.8180.06232>10.00.0012 488ANN STAT0090-53649434 2.307 3.0940.614101>10.00.03112 489ANN SURG0003-4932316498.469.776 1.0642508.70.06737 490ANN SURG ONCOL1068-92658085 3.898 4.5070.976420 4.60.02695 491ANN TELECOMMUN0003-43472380.3330.2930.05753 6.80.00073 492ANN THORAC SURG0003-497525835 2.689 2.5920.6996807.20.06851 493ANN TROP MED PARASIT0003-49832494 1.652 1.4720.12596>10.00.00447 494ANN TROP PAEDIATR0272-49367220.949 1.0040.1464190.00179 495ANN UROL0003-44011840.2260.2219.60.00022 496ANN VASC SURG0890-******** 1.262 1.7510.18128 6.60.00747 497ANN ZOOL0003-45412470.3970.3750.014697.40.00064 498ANN ZOOL FENN0003-455X1358 1.21 1.5630.2556>10.00.00392 499ANNU REV ASTRON ASTR0066-4146628025.82624.370.69213>10.00.02337 500ANNU REV BIOCHEM0066-41541688930.01634.372 3.677319.70.06856 501ANNU REV BIOMED ENG1523-9829212210.78913.679115 5.60.00951。